SIRT Family: Biological Functions and Therapeutic Targets

Abstract

Sirtuins (SIRT1–SIRT7) are nicotinamide adenine dinucleotide (NAD⁺) dependent deacylases that serves as metabolic sensors, coupling cellular energy status to chromatin structure, mitochondrial function, and stress responses. Dysregulated SIRT activity has been extensively studied in aging, metabolic syndrome, cardiovascular disease, neurodegeneration, cancer, and immune disorders. However, robust human evidence and SIRT-targeted therapies are lacking. Transgenic mouse models serve as key platforms to study gene function and guide therapeutic development. This review synthesizes evidence from Sirt1–7 transgenic mouse models regarding the core cellular processes governed by SIRTs: metabolism, genome integrity, stress resistance, immunity, and autophagy, and illustrates their operation across different organ systems. By comparing global, tissue-specific, and inducible knockout (KO) and overexpression (OE) models of cardiovascular, respiratory, digestive, nervous, endocrine, urogenital, musculoskeletal, malignant, and immune diseases, we identified central regulatory SIRTs (SIRT1, SIRT3, and SIRT6), context-dependent modifiers (SIRT2, SIRT4, SIRT5, and SIRT7), and their organ- and cell type-specific functions. We also summarize representative small-molecule SIRT activators, inhibitors, and degraders, covering both clinical and preclinical studies, and highlight where contradictions and knowledge gaps remain. Together, these analyses help clarify which aspects of SIRT modulation are most promising and under what isoform, tissue, and disease contexts they should be pursued for the development of SIRT-targeted therapies in human disease.

Keywords

inflammation / metabolism / Sirtuins / transgenic mouse model / therapeutic targets

References

[1] R. A. Frye, “Phylogenetic Classification of Prokaryotic and Eukaryotic Sir2-Like Proteins,” Biochemical and Biophysical Research Communications 273 (2000): 793–798.

[2] M. Kaeberlein, M. Mcvey, and L. Guarente, “The Sir2/3/4 Complex and Sir2 Alone Promote Longevity in Saccharomyces Cerevisiae by Two Different Mechanisms,” Genes & Development 13 (1999): 2570–2580.

[3] T. C. Pereira, E. P. Rico, D. B. Rosemberg, et al., “Zebrafish as a Model Organism to Evaluate Drugs Potentially Able to Modulate Sirtuin Expression,” Zebrafish 8 (2011): 9–16.

[4] S. Michan and D. Sinclair, “Sirtuins in Mammals: Insights Into Their Biological Function,” Biochemical Journal 404 (2007): 1–13.

[5] B. Chen, W. Zang, J. Wang, et al., “The Chemical Biology of Sirtuins,” Chemical Society Reviews 44 (2015): 5246–5264.

[6] P. Bheda, H. Jing, C. Wolberger, et al., “The Substrate Specificity of Sirtuins,” Annual Review of Biochemistry 85 (2016): 405–429.

[7] D. Rauh, F. Fischer, M. Gertz, et al., “An Acetylome Peptide Microarray Reveals Specificities and Deacetylation Substrates for all Human Sirtuin Isoforms,” Nature Communications 4 (2013): 2327.

[8] Y. B. Teng, H. Jing, P. Aramsangtienchai, et al., “Efficient Demyristoylase Activity of Sirt2 Revealed by Kinetic and Structural Studies,” Scientific Reports 5 (2015): 8529.

[9] M. Pannek, Z. Simic, M. Fuszard, et al., “Crystal Structures of the Mitochondrial Deacylase Sirtuin 4 Reveal Isoform-Specific Acyl Recognition and Regulation Features,” Nature Communications 8 (2017): 1513.

[10] K. A. Anderson, F. K. Huynh, K. Fisher-Wellman, et al., “Sirt4 Is a Lysine Deacylase That Controls Leucine Metabolism and Insulin Secretion,” Cell Metabolism 25 (2017): 838–855 e15.

[11] J. Du, Y. Zhou, X. Su, et al., “Sirt5 Is a Nad-Dependent Protein Lysine Demalonylase and Desuccinylase,” Science 334 (2011): 806–809.

[12] S. Kumar and D. B. Lombard, “Functions of the Sirtuin Deacylase Sirt5 in Normal Physiology and Pathobiology,” Critical Reviews in Biochemistry and Molecular Biology 53 (2018): 311–334.

[13] P. W. Pan, J. L. Feldman, M. K. Devries, et al., “Structure and Biochemical Functions of Sirt6,” Journal of Biological Chemistry 286 (2011): 14575–14587.

[14] H. Jiang, S. Khan, Y. Wang, et al., “Sirt6 Regulates Tnf-Alpha Secretion Through Hydrolysis of Long-Chain Fatty Acyl Lysine,” Nature 496 (2013): 110–113.

[15] L. Li, L. Shi, S. Yang, et al., “Sirt7 Is a Histone Desuccinylase That Functionally Links to Chromatin Compaction and Genome Stability,” Nature Communications 7 (2016): 12235.

[16] N. G. Simonet, J. K. Thackray, B. N. Vazquez, et al., “Sirt7 Auto-Adp-Ribosylation Regulates Glucose Starvation Response Through Mh2a1,” Science Advances 6 (2020): eaaz2590.

[17] J. E. Bolding, A. L. Nielsen, I. Jensen, et al., “Substrates and Cyclic Peptide Inhibitors of the Oligonucleotide-Activated Sirtuin 7,” Angewandte Chemie 62 (2023): e202314597.

[18] Q. J. Wu, T. N. Zhang, H. H. Chen, et al., “The Sirtuin Family in Health and Disease,” Signal Transduct Target Ther 7 (2022): 402.

[19] A. S. Banks, N. Kon, C. Knight, et al., “Sirt1 Gain of Function Increases Energy Efficiency and Prevents Diabetes in Mice,” Cell Metabolism 8 (2008): 333–341.

[20] L. Bordone, D. Cohen, A. Robinson, et al., “Sirt1 Transgenic Mice Show Phenotypes Resembling Calorie Restriction,” Aging Cell 6 (2007): 759–767.

[21] M. W. Mcburney, X. Yang, K. Jardine, et al., “The Mammalian Sir2alpha Protein Has a Role in Embryogenesis and Gametogenesis,” Molecular and Cellular Biology 23 (2003): 38–54.

[22] H. L. Cheng, R. Mostoslavsky, S. Saito, et al., “Developmental Defects and P53 Hyperacetylation in Sir2 Homolog (Sirt1)-Deficient Mice,” PNAS 100 (2003): 10794–10799.

[23] E. L. Seifert, A. Z. Caron, K. Morin, et al., “Sirt1 Catalytic Activity Is Required for Male Fertility and Metabolic Homeostasis in Mice,” Faseb Journal 26 (2012): 555–566.

[24] A. Z. Caron, X. He, W. Mottawea, et al., “The Sirt1 Deacetylase Protects Mice Against the Symptoms of Metabolic Syndrome,” Faseb Journal 28 (2014): 1306–1316.

[25] P. A. Gorski, S. P. Jang, and D. Jeong, “Correction to: Role of Sirt1 in Modulating Acetylation of the Sarco- Endoplasmic Reticulum Ca(2+)-Atpase in Heart Failure,” Circulation Research 124 (2019): e149.

[26] R. H. Wang, H. S. Kim, C. Xiao, et al., “Hepatic Sirt1 Deficiency in Mice Impairs Mtorc2/Akt Signaling and Results in Hyperglycemia, Oxidative Damage, and Insulin Resistance,” Journal of Clinical Investigation 121 (2011): 4477–4490.

[27] M. P. Gillum, M. E. Kotas, D. M. Erion, et al., “Sirt1 Regulates Adipose Tissue Inflammation,” Diabetes 60 (2011): 3235–3245.

[28] L. Luu, F. F. Dai, K. J. Prentice, et al., “The Loss of Sirt1 in Mouse Pancreatic Beta Cells Impairs Insulin Secretion by Disrupting Glucose Sensing,” Diabetologia 56 (2013): 2010–2020.

[29] A. T. White, C. E. Mccurdy, A. Philp, et al., “Skeletal Muscle-Specific Overexpression of Sirt1 Does Not Enhance Whole-Body Energy Expenditure or Insulin Sensitivity in Young Mice,” Diabetologia 56 (2013): 1629–1637.

[30] L. Lantier, A. S. Williams, C. C. Hughey, et al., “Sirt2 Knockout Exacerbates Insulin Resistance in High Fat-Fed Mice,” PLoS ONE 13 (2018): e0208634.

[31] L. Yang, J. Zhang, W. Xing, et al., “Sirt3 Deficiency Induces Endothelial Insulin Resistance and Blunts Endothelial-Dependent Vasorelaxation in Mice and Human With Obesity,” Scientific Reports 6 (2016): 23366.

[32] L. Lantier, A. S. Williams, I. M. Williams, et al., “Sirt3 Is Crucial for Maintaining Skeletal Muscle Insulin Action and Protects Against Severe Insulin Resistance in High-Fat-Fed Mice,” Diabetes 64 (2015): 3081–3092.

[33] E. Jing, B. Emanuelli, M. D. Hirschey, et al., “Sirtuin-3 (Sirt3) Regulates Skeletal Muscle Metabolism and Insulin Signaling via Altered Mitochondrial Oxidation and Reactive Oxygen Species Production,” PNAS 108 (2011): 14608–14613.

[34] M. Chen, S. Hui, H. Lang, et al., “Sirt3 Deficiency Promotes High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Correlation With Impaired Intestinal Permeability Through Gut Microbial Dysbiosis,” Molecular Nutrition & Food Research 63 (2019): e1800612.

[35] L. C. Porter, M. P. Franczyk, T. Pietka, et al., “Nad(+)-Dependent Deacetylase Sirt3 in Adipocytes Is Dispensable for Maintaining Normal Adipose Tissue Mitochondrial Function and Whole Body Metabolism,” American Journal of Physiology. Endocrinology and Metabolism 315 (2018): E520–E530.

[36] J. Chen, Y. Zhang, J. Gao, et al., “Sirtuin 3 Deficiency Exacerbates Age-Related Periodontal Disease,” Journal of Periodontal Research 56 (2021): 1163–1173.

[37] A. E. Dikalova, A. Pandey, L. Xiao, et al., “Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress,” Circulation Research 126 (2020): 439–452.

[38] K. D. Brown, S. Maqsood, J. Y. Huang, et al., “Activation of Sirt3 by the Nad(+) Precursor Nicotinamide Riboside Protects From Noise-Induced Hearing Loss,” Cell Metabolism 20 (2014): 1059–1068.

[39] X. Ming, A. C. K. Chung, D. Mao, et al., “Pancreatic Sirtuin 3 Deficiency Promotes Hepatic Steatosis by Enhancing 5-Hydroxytryptamine Synthesis in Mice With Diet-Induced Obesity,” Diabetes 70 (2021): 119–131.

[40] B. Osborne, J. Reznick, L. E. Wright, et al., “Liver-Specific Overexpression of Sirt3 Enhances Oxidative Metabolism, but Does Not Impact Metabolic Defects Induced by High Fat Feeding in Mice,” Biochemical and Biophysical Research Communications 607 (2022): 131–137.

[41] C. J. Oldfield, T. L. Moffatt, K. A. O'hara, et al., “Muscle-Specific Sirtuin 3 Overexpression Does Not Attenuate the Pathological Effects of High-Fat/High-Sucrose Feeding but Does Enhance Cardiac Serca2a Activity,” Physiological Reports 9 (2021): e14961.

[42] P. J. Fernandez-Marcos, E. H. Jeninga, C. Canto, et al., “Muscle or Liver-Specific Sirt3 Deficiency Induces Hyperacetylation of Mitochondrial Proteins Without Affecting Global Metabolic Homeostasis,” Scientific Reports 2 (2012): 425.

[43] M. C. Haigis, R. Mostoslavsky, K. M. Haigis, et al., “Sirt4 Inhibits Glutamate Dehydrogenase and Opposes the Effects of Calorie Restriction in Pancreatic Beta Cells,” Cell 126 (2006): 941–954.

[44] F. K. Huynh, B. S. Peterson, K. A. Anderson, et al., “Beta-Cell-Specific Ablation of Sirtuin 4 Does Not Affect Nutrient-Stimulated Insulin Secretion in Mice,” American Journal of Physiology. Endocrinology and Metabolism 319 (2020): E805–E813.

[45] L. Ho, A. S. Titus, K. K. Banerjee, et al., “Sirt4 Regulates Atp Homeostasis and Mediates a Retrograde Signaling via Ampk,” Aging (Albany NY) 5 (2013): 835–849.

[46] G. Laurent, V. C. De Boer, L. W. Finley, et al., “Sirt4 Represses Peroxisome Proliferator-Activated Receptor Alpha Activity to Suppress Hepatic Fat Oxidation,” Molecular and Cellular Biology 33 (2013): 4552–4561.

[47] N. L. Bentley, C. E. Fiveash, B. Osborne, et al., “Protein Hypoacylation Induced by Sirt5 Overexpression Has Minimal Metabolic Effect in Mice,” Biochemical and Biophysical Research Communications 503 (2018): 1349–1355.

[48] J. Yu, S. Sadhukhan, L. G. Noriega, et al., “Metabolic Characterization of a Sirt5 Deficient Mouse Model,” Scientific Reports 3 (2013): 2806.

[49] M. Ogura, Y. Nakamura, D. Tanaka, et al., “Overexpression of Sirt5 Confirms Its Involvement in Deacetylation and Activation of Carbamoyl Phosphate Synthetase 1,” Biochemical and Biophysical Research Communications 393 (2010): 73–78.

[50] T. Nakagawa, D. J. Lomb, M. C. Haigis, et al., “Sirt5 Deacetylates Carbamoyl Phosphate Synthetase 1 and Regulates the Urea Cycle,” Cell 137 (2009): 560–570.

[51] Y. Du, H. Hu, S. Qu, et al., “Sirt5 Deacylates Metabolism-Related Proteins and Attenuates Hepatic Steatosis in Ob/Ob Mice,” EBioMedicine 36 (2018): 347–357.

[52] D. P. Bhatt, C. A. Mills, K. A. Anderson, et al., “Deglutarylation of Glutaryl-Coa Dehydrogenase by Deacylating Enzyme Sirt5 Promotes Lysine Oxidation in Mice,” Journal of Biological Chemistry 298 (2022): 101723.

[53] T. Nakagawa and L. Guarente, “Urea Cycle Regulation by Mitochondrial Sirtuin, Sirt5,” Aging (Albany NY) 1 (2009): 578–581.

[54] C. Xiao, H. S. Kim, T. Lahusen, et al., “Sirt6 Deficiency Results in Severe Hypoglycemia by Enhancing both Basal and Insulin-Stimulated Glucose Uptake in Mice,” Journal of Biological Chemistry 285 (2010): 36776–36784.

[55] R. Mostoslavsky, K. F. Chua, D. B. Lombard, et al., “Genomic Instability and Aging-Like Phenotype in the Absence of Mammalian Sirt6,” Cell 124 (2006): 315–329.

[56] Y. Kanfi, S. Naiman, G. Amir, et al., “The Sirtuin Sirt6 Regulates Lifespan in Male Mice,” Nature 483 (2012): 218–221.

[57] Y. Kanfi, V. Peshti, R. Gil, et al., “Sirt6 Protects Against Pathological Damage Caused by Diet-Induced Obesity,” Aging Cell 9 (2010): 162–173.

[58] K. Qin, N. Zhang, Z. Zhang, et al., “Sirt6-Mediated Transcriptional Suppression of Txnip Is Critical for Pancreatic Beta Cell Function and Survival in Mice,” Diabetologia 61 (2018): 906–918.

[59] D. Wu, I. H. Bang, B. H. Park, et al., “Loss of Sirt6 in Adipocytes Impairs the Ability of Adipose Tissue to Adapt to Intermittent Fasting,” Experimental & Molecular Medicine 53 (2021): 1298–1306.

[60] C. Zhu, M. Huang, H. G. Kim, et al., “Sirt6 Controls Hepatic Lipogenesis by Suppressing Lxr, Chrebp, and Srebp1,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1867 (2021): 166249.

[61] J. Fang, A. Ianni, C. Smolka, et al., “Sirt7 Promotes Adipogenesis in the Mouse by Inhibiting Autocatalytic Activation of Sirt1,” PNAS 114 (2017): E8352–E8361.

[62] J. Shin, M. He, Y. Liu, et al., “Sirt7 Represses Myc Activity to Suppress Er Stress and Prevent Fatty Liver Disease,” Cell Reports 5 (2013): 654–665.

[63] O. Vakhrusheva, C. Smolka, P. Gajawada, et al., “Sirt7 Increases Stress Resistance of Cardiomyocytes and Prevents Apoptosis and Inflammatory Cardiomyopathy in Mice,” Circulation Research 102 (2008): 703–710.

[64] T. Yoshizawa, M. F. Karim, Y. Sato, et al., “Sirt7 Controls Hepatic Lipid Metabolism by Regulating the Ubiquitin-Proteasome Pathway,” Cell Metabolism 19 (2014): 712–721.

[65] R. H. Wang, K. Sengupta, C. Li, et al., “Impaired DNA Damage Response, Genome Instability, and Tumorigenesis in Sirt1 Mutant Mice,” Cancer Cell 14 (2008): 312–323.

[66] I. Gorenne, S. Kumar, K. Gray, et al., “Vascular Smooth Muscle Cell Sirtuin 1 Protects Against DNA Damage and Inhibits Atherosclerosis,” Circulation 127 (2013): 386–396.

[67] M. J. Powell, M. C. Casimiro, C. Cordon-Cardo, et al., “Disruption of a Sirt1-Dependent Autophagy Checkpoint in the Prostate Results in Prostatic Intraepithelial Neoplasia Lesion Formation,” Cancer Research 71 (2011): 964–975.

[68] I. Hamaidi, L. Zhang, N. Kim, et al., “Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells,” Cell metabolism 32 (2020): 420–436 e12.

[69] T. Heinonen, E. Ciarlo, E. Rigoni, et al., “Dual Deletion of the Sirtuins Sirt2 and Sirt3 Impacts on Metabolism and Inflammatory Responses of Macrophages and Protects From Endotoxemia,” Frontiers in immunology 10 (2019): 2713.

[70] L. Serrano, P. Martinez-Redondo, A. Marazuela-Duque, et al., “The Tumor Suppressor Sirt2 Regulates Cell Cycle Progression and Genome Stability by Modulating the Mitotic Deposition of H4k20 Methylation,” Genes & development 27 (2013): 639–653.

[71] H. S. Kim, A. Vassilopoulos, R. H. Wang, et al., “Sirt2 Maintains Genome Integrity and Suppresses Tumorigenesis Through Regulating Apc/C Activity,” Cancer Cell 20 (2011): 487–499.

[72] P. Cheresh, S. J. Kim, R. Jablonski, et al., “Sirt3 Overexpression Ameliorates Asbestos-Induced Pulmonary Fibrosis, Mt-DNA Damage, and Lung Fibrogenic Monocyte Recruitment,” International Journal of Molecular Sciences 22 (2021): 6856.

[73] R. P. Jablonski, S. J. Kim, P. Cheresh, et al., “Sirt3 Deficiency Promotes Lung Fibrosis by Augmenting Alveolar Epithelial Cell Mitochondrial DNA Damage and Apoptosis,” Faseb Journal 31 (2017): 2520–2532.

[74] V. B. Pillai, S. Bindu, W. Sharp, et al., “Sirt3 Protects Mitochondrial DNA Damage and Blocks the Development of Doxorubicin-Induced Cardiomyopathy in Mice,” American Journal of Physiology. Heart and Circulatory Physiology 310 (2016): H962–H972.

[75] L. Du, X. Liu, Y. Ren, et al., “Loss of Sirt4 Promotes the Self-Renewal of Breast Cancer Stem Cells,” Theranostics 10 (2020): 9458–9476.

[76] Y. S. Wang, L. Du, X. Liang, et al., “Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine-Monophosphate-Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice,” Hepatology 69 (2019): 1614–1631.

[77] S. M. Jeong, A. Lee, J. Lee, et al., “Sirt4 Protein Suppresses Tumor Formation in Genetic Models of Myc-Induced B Cell Lymphoma,” Journal of Biological Chemistry 289 (2014): 4135–4144.

[78] X. F. Chen, M. X. Tian, R. Q. Sun, et al., “Sirt5 Inhibits Peroxisomal Acox1 to Prevent Oxidative Damage and Is Downregulated in Liver Cancer,” Embo Reports 19 (2018): e45124.

[79] S. Kugel, C. Sebastian, J. Fitamant, et al., “Sirt6 Suppresses Pancreatic Cancer Through Control of Lin28b,” Cell 165 (2016): 1401–1415.

[80] J. U. Marquardt, K. Fischer, K. Baus, et al., “Sirtuin-6-Dependent Genetic and Epigenetic Alterations Are Associated With Poor Clinical Outcome in Hepatocellular Carcinoma Patients,” Hepatology 58 (2013): 1054–1064.

[81] J. E. Choi, C. Sebastian, C. M. Ferrer, et al., “A Unique Subset of Glycolytic Tumour-Propagating Cells Drives Squamous Cell Carcinoma,” Nature Metabolism 3 (2021): 182–195.

[82] P. Becherini, I. Caffa, F. Piacente, et al., “Sirt6 Enhances Oxidative Phosphorylation in Breast Cancer and Promotes Mammary Tumorigenesis in Mice,” Cancer & Metabolism 9 (2021): 6.

[83] B. N. Vazquez, J. K. Thackray, N. G. Simonet, et al., “Sirt7 Promotes Genome Integrity and Modulates Non-Homologous End Joining DNA Repair,” Embo Journal 35 (2016): 1488–1503.

[84] A. J. Wang, Y. Tang, J. Zhang, et al., “Cardiac Sirt1 Ameliorates Doxorubicin-Induced Cardiotoxicity by Targeting Sestrin 2,” Redox Biology 52 (2022): 102310.

[85] H. Y. Yang, F. Z. Lin, H. W. Yang, et al., “The Effect of Sirt1 Deficiency on Ca(2+) and Na(+) Regulation in Mouse Ventricular Myocytes,” Journal of Cellular and Molecular Medicine 24 (2020): 6762–6772.

[86] Y. J. Hsu, S. C. Hsu, C. P. Hsu, et al., “Sirtuin 1 Protects the Aging Heart From Contractile Dysfunction Mediated Through the Inhibition of Endoplasmic Reticulum Stress-Mediated Apoptosis in Cardiac-Specific Sirtuin 1 Knockout Mouse Model,” International Journal of Cardiology 228 (2017): 543–552.

[87] X. Yuan, H. Qi, X. Li, et al., “Disruption of Spatiotemporal Hypoxic Signaling Causes Congenital Heart Disease in Mice,” Journal of Clinical Investigation 127 (2017): 2235–2248.

[88] X. Bai, Y. Liu, J. Liu, et al., “Adscs-Derived Exosomes Suppress Macrophage Ferroptosis via the Sirt1/Nrf2 Signaling Axis to Alleviate Acute Lung Injury in Sepsis,” International Immunopharmacology 146 (2025): 113914.

[89] S. Zheng, J. Jiang, Z. Shu, et al., “Fine Particulate Matter (Pm(2.5)) Induces Testosterone Disruption by Triggering Ferroptosis Through Sirt1/Hif-1alpha Signaling Pathway in Male Mice,” Free Radical Biology and Medicine 221 (2024): 40–51.

[90] L. T. Nguyen, C. H. Mak, H. Chen, et al., “Sirt1 Attenuates Kidney Disorders in Male Offspring due to Maternal High-Fat Diet,” Nutrients 11 (2019): 146.

[91] R. Liu, Y. Zhong, X. Li, et al., “Role of Transcription Factor Acetylation in Diabetic Kidney Disease,” Diabetes 63 (2014): 2440–2453.

[92] P. Li, Y. Liu, X. Qin, et al., “Sirt1 Attenuates Renal Fibrosis by Repressing Hif-2alpha,” Cell Death Discovery 7 (2021): 59.

[93] J. D. Iljas, Z. Wei, and H. A. Homer, “Sirt1 Sustains Female Fertility by Slowing Age-Related Decline in Oocyte Quality Required for Post-Fertilization Embryo Development,” Aging Cell 19 (2020): e13204.

[94] H. Su, A. C. Cantrell, J. X. Chen, et al., “Sirt3 Deficiency Enhances Ferroptosis and Promotes Cardiac Fibrosis via P53 Acetylation,” Cells 12 (2023): 1428.

[95] X. Cao, Y. Wu, H. Hong, et al., “Sirtuin 3 Dependent and Independent Effects of Nad(+) to Suppress Vascular Inflammation and Improve Endothelial Function in Mice,” Antioxidants (Basel) 11 (2022): 706.

[96] M. M. Tomczyk, K. G. Cheung, B. Xiang, et al., “Mitochondrial Sirtuin-3 (Sirt3) Prevents Doxorubicin-Induced Dilated Cardiomyopathy by Modulating Protein Acetylation and Oxidative Stress,” Circulation: Heart Failure 15 (2022): e008547.

[97] D. S. Gaul, J. Weber, L. J. Van Tits, et al., “Loss of Sirt3 Accelerates Arterial Thrombosis by Increasing Formation of Neutrophil Extracellular Traps and Plasma Tissue Factor Activity,” Cardiovascular Research 114 (2018): 1178–1188.

[98] A. E. Dikalova, H. A. Itani, R. R. Nazarewicz, et al., “Sirt3 Impairment and Sod2 Hyperacetylation in Vascular Oxidative Stress and Hypertension,” Circulation Research 121 (2017): 564–574.

[99] K. Zhang, Y. Wang, Y. Sun, et al., “Sirtuin 3 Reinforces Acylcarnitine Metabolism and Maintains Thermogenesis in Brown Adipose Tissue of Aging Mice,” Aging Cell 23 (2024): e14332.

[100] L. J. Smulan, N. Martinez, M. C. Kiritsy, et al., “Sirtuin 3 Downregulation in Mycobacterium Tuberculosis-Infected Macrophages Reprograms Mitochondrial Metabolism and Promotes Cell Death,” MBio 12 (2021): e03140–e03220.

[101] Y. J. Kim, S. H. Lee, S. M. Jeon, et al., “Sirtuin 3 Is Essential for Host Defense Against Mycobacterium Abscessus Infection Through Regulation of Mitochondrial Homeostasis,” Virulence 11 (2020): 1225–1239.

[102] Q. Zhang, X. Liu, N. Li, et al., “Sirtuin 3 Deficiency Aggravates Contrast-Induced Acute Kidney Injury,” Journal of Translational Medicine 16 (2018): 313.

[103] Y. Zhou, A. C. K. Chung, R. Fan, et al., “Sirt3 Deficiency Increased the Vulnerability of Pancreatic Beta Cells to Oxidative Stress-Induced Dysfunction,” Antioxid Redox Signaling 27 (2017): 962–976.

[104] Y. Fu, M. Kinter, J. Hudson, et al., “Aging Promotes Sirtuin 3-Dependent Cartilage Superoxide Dismutase 2 Acetylation and Osteoarthritis,” Arthritis Rheumatol 68 (2016): 1887–1898.

[105] M. C. Coleman, A. K. Olivier, J. A. Jacobus, et al., “Superoxide Mediates Acute Liver Injury in Irradiated Mice Lacking Sirtuin 3,” Antioxid Redox Signaling 20 (2014): 1423–1435.

[106] L. E. Greiten, B. Zhang, C. M. Roos, et al., “Sirtuin 6 Protects Against Oxidative Stress and Vascular Dysfunction in Mice,” Frontiers in Physiology 12 (2021): 753501.

[107] S. Wu, J. Lan, L. Li, et al., “Sirt6 Protects Cardiomyocytes Against Doxorubicin-Induced Cardiotoxicity by Inhibiting P53/Fas-Dependent Cell Death and Augmenting Endogenous Antioxidant Defense Mechanisms,” Cell Biology and Toxicology 39 (2023): 237–258.

[108] J. Luo, H. Liu, Y. Xu, et al., “Hepatic Sirt6 Activation Abrogates Acute Liver Failure,” Cell death & disease 15 (2024): 283.

[109] S. Yang, L. Chen, S. Din, et al., “The Sirt6/Bap1/Xct Signaling Axis Mediates Ferroptosis in Cisplatin-Induced Aki,” Cell Signalling 125 (2025): 111479.

[110] J. Guo, J. Xu, L. Chen, et al., “Role of Sirt2 in Intestinal Barrier Under Cold Exposure,” Life Sciences 330 (2023): 121949.

[111] Y. Liu, H. Cui, C. Mei, et al., “Sirtuin4 Alleviates Severe Acute Pancreatitis by Regulating Hif-1alpha/Ho-1 Mediated Ferroptosis,” Cell death & disease 14 (2023): 694.

[112] J. Adjei-Mosi, Q. Sun, S. B. Smithson, et al., “Age-Dependent Loss of Hepatic Sirt1 Enhances Nlrp3 Inflammasome Signaling and Impairs Capacity for Liver Fibrosis Resolution,” Aging Cell 22 (2023): e13811.

[113] Y. Han, W. Sun, D. Ren, et al., “Sirt1 Agonism Modulates Cardiac Nlrp3 Inflammasome Through Pyruvate Dehydrogenase during Ischemia and Reperfusion,” Redox Biology 34 (2020): 101538.

[114] Y. N. Shu, L. H. Dong, H. Li, et al., “Ckii-Sirt1-Sm22alpha Loop Evokes a Self-Limited Inflammatory Response in Vascular Smooth Muscle Cells,” Cardiovascular Research 113 (2017): 1198–1207.

[115] H. Z. Chen, F. Wang, P. Gao, et al., “Age-Associated Sirtuin 1 Reduction in Vascular Smooth Muscle Links Vascular Senescence and Inflammation to Abdominal Aortic Aneurysm,” Circulation Research 119 (2016): 1076–1088.

[116] J. L. Fry, L. Al Sayah, R. M. Weisbrod, et al., “Vascular Smooth Muscle Sirtuin-1 Protects Against Diet-Induced Aortic Stiffness,” Hypertension 68 (2016): 775–784.

[117] A. S. Wellman, M. R. Metukuri, N. Kazgan, et al., “Intestinal Epithelial Sirtuin 1 Regulates Intestinal Inflammation During Aging in Mice by Altering the Intestinal Microbiota,” Gastroenterology 153 (2017): 772–786.

[118] M. Ming, B. Zhao, C. R. Shea, et al., “Loss of Sirtuin 1 (Sirt1) Disrupts Skin Barrier Integrity and Sensitizes Mice to Epicutaneous Allergen Challenge,” Journal of Allergy and Clinical Immunology 135 (2015): 936–945 e4.

[119] T. Jiang, T. Qin, P. Gao, et al., “Sirt1 Attenuates Blood-Spinal Cord Barrier Disruption After Spinal Cord Injury by Deacetylating P66shc,” Redox Biology 60 (2023): 102615.

[120] A. Legutko, T. Marichal, L. Fievez, et al., “Sirtuin 1 Promotes Th2 Responses and Airway Allergy by Repressing Peroxisome Proliferator-Activated Receptor-Gamma Activity in Dendritic Cells,” Journal of Immunology 187 (2011): 4517–4529.

[121] T. Lai, G. Su, D. Wu, et al., “Myeloid-Specific Sirt1 Deletion Exacerbates Airway Inflammatory Response in a Mouse Model of Allergic Asthma,” Aging (Albany NY) 13 (2021): 15479–15490.

[122] S. Elesela, S. B. Morris, S. Narayanan, et al., “Sirtuin 1 Regulates Mitochondrial Function and Immune Homeostasis in Respiratory Syncytial Virus Infected Dendritic Cells,” Plos Pathogens 16 (2020): e1008319.

[123] A. B. Owczarczyk, M. A. Schaller, M. Reed, et al., “Sirtuin 1 Regulates Dendritic Cell Activation and Autophagy during Respiratory Syncytial Virus-Induced Immune Responses,” Journal of Immunology 195 (2015): 1637–1646.

[124] Y. G. Lee, B. F. Reader, D. Herman, et al., “Sirtuin 2 Enhances Allergic Asthmatic Inflammation,” JCI Insight 4 (2019): e124710.

[125] G. Lo Sasso, K. J. Menzies, A. Mottis, et al., “Sirt2 Deficiency Modulates Macrophage Polarization and Susceptibility to Experimental Colitis,” PLoS ONE 9 (2014): e103573.

[126] L. Chen, D. Li, Z. Zhan, et al., “Sirtuin 2 Exacerbates Renal Tubule Injury and Inflammation in Diabetic Mice via Deacetylation of C-Jun/C-Fos,” Cellular and Molecular Life Sciences 82 (2025): 45.

[127] Y. J. Jung, W. Park, K. P. Kang, et al., “Sirt2 Is Involved in Cisplatin-Induced Acute Kidney Injury Through Regulation of Mitogen-Activated Protein Kinase Phosphatase-1,” Nephrology, Dialysis, Transplantation 35 (2020): 1145–1156.

[128] X. Palomer, M. S. Roman-Azcona, J. Pizarro-Delgado, et al., “Sirt3-Mediated Inhibition of Fos Through Histone H3 Deacetylation Prevents Cardiac Fibrosis and Inflammation,” Signal Transduction and Targeted Therapy 5 (2020): 14.

[129] S. Zhao, J. Li, X. Xing, et al., “Oxyberberine Suppressed the Carbon Tetrachloride-Induced Liver Fibrosis by Inhibiting Liver Inflammation in a Sirtuin 3-Dependent Manner in Mice,” International Immunopharmacology 116 (2023): 109876.

[130] F. V. Lobianco, K. J. Krager, G. S. Carter, et al., “The Role of Sirtuin 3 in Radiation-Induced Long-Term Persistent Liver Injury,” Antioxidants (Basel) 9 (2020): 409.

[131] D. Kurundkar, A. R. Kurundkar, N. B. Bone, et al., “Sirt3 Diminishes Inflammation and Mitigates Endotoxin-Induced Acute Lung Injury,” JCI Insight 4 (2019): e120722.

[132] K. Qin, C. Han, H. Zhang, et al., “Nad(+) Dependent Deacetylase Sirtuin 5 Rescues the Innate Inflammatory Response of Endotoxin Tolerant Macrophages by Promoting Acetylation of P65,” Journal of Autoimmunity 81 (2017): 120–129.

[133] T. Heinonen, E. Ciarlo, D. L. E. Roy, et al., “Impact of the Dual Deletion of the Mitochondrial Sirtuins Sirt3 and Sirt5 on Anti-Microbial Host Defenses,” Frontiers in immunology 10 (2019): 2341.

[134] S. J. Woo, H. S. Noh, N. Y. Lee, et al., “Myeloid Sirtuin 6 Deficiency Accelerates Experimental Rheumatoid Arthritis by Enhancing Macrophage Activation and Infiltration Into Synovium,” EBioMedicine 38 (2018): 228–237.

[135] H. Y. Jang, D. H. Ha, S. Y. Rah, et al., “Sirtuin 6 Is a Negative Regulator of Fcepsilonri Signaling and Anaphylactic Responses,” Journal of Allergy and Clinical Immunology 149 (2022): 156–167 e7.

[136] L. Chen, Q. Liu, Q. Tang, et al., “Hepatocyte-Specific Sirt6 Deficiency Impairs Ketogenesis,” Journal of Biological Chemistry 294 (2019): 1579–1589.

[137] J. Jin, W. Li, T. Wang, et al., “Loss of Proximal Tubular Sirtuin 6 Aggravates Unilateral Ureteral Obstruction-Induced Tubulointerstitial Inflammation and Fibrosis by Regulation of Beta-Catenin Acetylation,” Cells 11 (2022): 1477.

[138] Z. Li, K. Xu, N. Zhang, et al., “Overexpressed Sirt6 Attenuates Cisplatin-Induced Acute Kidney Injury by Inhibiting Erk1/2 Signaling,” Kidney International 93 (2018): 881–892.

[139] A. Sanchez-Navarro, M. A. Martinez-Rojas, A. Albarran-Godinez, et al., “Sirtuin 7 Deficiency Reduces Inflammation and Tubular Damage Induced by an Episode of Acute Kidney Injury,” International Journal of Molecular Sciences 23 (2022): 2573.

[140] Y. Miyasato, T. Yoshizawa, Y. Sato, et al., “Sirtuin 7 Deficiency Ameliorates Cisplatin-Induced Acute Kidney Injury Through Regulation of the Inflammatory Response,” Scientific Reports 8 (2018): 5927.

[141] J. Xiang, N. Zhang, H. Sun, et al., “Disruption of Sirt7 Increases the Efficacy of Checkpoint Inhibitor via Mef2d Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells,” Gastroenterology 158 (2020): 664–678 e24.

[142] A. Sathyanarayan, M. T. Mashek, and D. G. Mashek, “Atgl Promotes Autophagy/Lipophagy via Sirt1 to Control Hepatic Lipid Droplet Catabolism,” Cell reports 19 (2017): 1–9.

[143] A. Prola, J. P. Da Silva, A. Guilbert, et al., “Sirt1 Protects the Heart From Er Stress-Induced Cell Death Through Eif2alpha Deacetylation,” Cell Death and Differentiation 24 (2017): 343–356.

[144] I. H. Lee, L. Cao, R. Mostoslavsky, et al., “A Role for the Nad-Dependent Deacetylase Sirt1 in the Regulation of Autophagy,” PNAS 105 (2008): 3374–3379.

[145] S. Kume, T. Uzu, K. Horiike, et al., “Calorie Restriction Enhances Cell Adaptation to Hypoxia Through Sirt1-Dependent Mitochondrial Autophagy in Mouse Aged Kidney,” Journal of Clinical Investigation 120 (2010): 1043–1055.

[146] W. Zhao, L. Zhang, R. Chen, et al., “Sirt3 Protects Against Acute Kidney Injury via Ampk/Mtor-Regulated Autophagy,” Frontiers in Physiology 9 (2018): 1526.

[147] C. Y. Wang, C. C. Chen, M. H. Lin, et al., “Tlr9 Binding to Beclin 1 and Mitochondrial Sirt3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart From Doxorubicin Toxicity,” Biology (Basel) 9 (2020): 369.

[148] Y. Yang, N. Li, T. Chen, et al., “Sirt3 Promotes Sensitivity to Sunitinib-Induced Cardiotoxicity via Inhibition of Gtsp1/Jnk/Autophagy Pathway in Vivo and in Vitro,” Archives of Toxicology 93 (2019): 3249–3260.

[149] J. Li, T. Chen, M. Xiao, et al., “Mouse Sirt3 Promotes Autophagy in Angii-Induced Myocardial Hypertrophy Through the Deacetylation of Foxo1,” Oncotarget 7 (2016): 86648–86659.

[150] Y. Li, Y. Ma, L. Song, et al., “Sirt3 Deficiency Exacerbates P53/Parkin-Mediated Mitophagy Inhibition and Promotes Mitochondrial Dysfunction: Implication for Aged Hearts,” International Journal of Molecular Medicine 41 (2018): 3517–3526.

[151] J. Gao, T. Wei, C. Huang, et al., “Sirtuin 3 Governs Autophagy-Dependent Glycolysis during Angiotensin Ii-Induced Endothelial-to-Mesenchymal Transition,” Faseb Journal 34 (2020): 16645–16661.

[152] Q. Liang, G. A. Benavides, A. Vassilopoulos, et al., “Bioenergetic and Autophagic Control by Sirt3 in Response to Nutrient Deprivation in Mouse Embryonic Fibroblasts,” Biochemical Journal 454 (2013): 249–257.

[153] S. Li, X. Dou, H. Ning, et al., “Sirtuin 3 Acts as a Negative Regulator of Autophagy Dictating Hepatocyte Susceptibility to Lipotoxicity,” Hepatology 66 (2017): 936–952.

[154] D. F. Silva, A. R. Esteves, C. R. Oliveira, et al., “Mitochondrial Metabolism Power Sirt2-Dependent Deficient Traffic Causing Alzheimer's-Disease Related Pathology,” Molecular Neurobiology 54 (2017): 4021–4040.

[155] G. Liu, S. H. Park, M. Imbesi, et al., “Loss of Nad-Dependent Protein Deacetylase Sirtuin-2 Alters Mitochondrial Protein Acetylation and Dysregulates Mitophagy,” Antioxid Redox Signaling 26 (2017): 849–863.

[156] X. Shen, X. Chen, J. Huang, et al., “Age-Dependent Role of Sirt6 in Jawbone via Regulating Senescence and Autophagy of Bone Marrow Stromal Cells,” Journal of Molecular Histology 51 (2020): 67–76.

[157] S. Araki, Y. Izumiya, T. Rokutanda, et al., “Sirt7 Contributes to Myocardial Tissue Repair by Maintaining Transforming Growth Factor-Beta Signaling Pathway,” Circulation 132 (2015): 1081–1093.

[158] C. Han, P. Linser, H. J. Park, et al., “Sirt1 Deficiency Protects Cochlear Cells and Delays the Early Onset of Age-Related Hearing Loss in C57bl/6 Mice,” Neurobiology of Aging 43 (2016): 58–71.

[159] O. Gabay, K. J. Zaal, C. Sanchez, et al., “Sirt1-Deficient Mice Exhibit an Altered Cartilage Phenotype,” Joint, Bone, Spine 80 (2013): 613–620.

[160] M. Sulaiman, M. J. Matta, N. R. Sunderesan, et al., “Resveratrol, an Activator of Sirt1, Upregulates Sarcoplasmic Calcium Atpase and Improves Cardiac Function in Diabetic Cardiomyopathy,” American Journal of Physiology. Heart and Circulatory Physiology 298 (2010): H833–H843.

[161] G. Laurent, N. J. German, A. K. Saha, et al., “Sirt4 Coordinates the Balance Between Lipid Synthesis and Catabolism by Repressing Malonyl Coa Decarboxylase,” Molecular Cell 50 (2013): 686–698.

[162] B. H. Ahn, H. S. Kim, S. Song, et al., “A Role for the Mitochondrial Deacetylase Sirt3 in Regulating Energy Homeostasis,” PNAS 105 (2008): 14447–14452.

[163] D. B. Lombard, F. W. Alt, H. L. Cheng, et al., “Mammalian Sir2 Homolog Sirt3 Regulates Global Mitochondrial Lysine Acetylation,” Molecular and Cellular Biology 27 (2007): 8807–8814.

[164] J. Guo, T. J. Pereira, Y. Mori, et al., “Resveratrol Inhibits Neointimal Growth After Arterial Injury in High-Fat-Fed Rodents: The Roles of Sirt1 and Ampk,” Journal of Vascular Research 57 (2020): 325–340.

[165] A. R. Bellin, Y. Zhang, K. Thai, et al., “Impaired Sirt1 Activity Leads to Diminution in Glomerular Endowment Without Accelerating Age-Associated Gfr Decline,” Physiological Reports 7 (2019): e14044.

[166] G. Di Sante, L. Wang, C. Wang, et al., “Sirt1-Deficient Mice Have Hypogonadotropic Hypogonadism due to Defective Gnrh Neuronal Migration,” Molecular Endocrinology 29 (2015): 200–212.

[167] M. Hernandez-Jimenez, O. Hurtado, M. I. Cuartero, et al., “Silent Information Regulator 1 Protects the Brain Against Cerebral Ischemic Damage,” Stroke; A Journal of Cerebral Circulation 44 (2013): 2333–2337.

[168] N. Buechler, X. Wang, B. K. Yoza, et al., “Sirtuin 2 Regulates Microvascular Inflammation during Sepsis,” Journal of Immunology Research 2017 (2017): 2648946.

[169] B. J. North, M. A. Rosenberg, K. B. Jeganathan, et al., “Sirt2 Induces the Checkpoint Kinase Bubr1 to Increase Lifespan,” Embo Journal 33 (2014): 1438–1453.

[170] H. X. Chen, X. C. Wang, H. T. Hou, et al., “Lysine Crotonylation of Serca2a Correlates to Cardiac Dysfunction and Arrhythmia in Sirt1 Cardiac-Specific Knockout Mice,” International Journal of Biological Macromolecules 242 (2023): 125151.

[171] X. Jin, Y. Zhang, Y. Zhou, et al., “Sirt1 Deficiency Promotes Age-Related Af Through Enhancing Atrial Necroptosis by Activation of Ripk1 Acetylation,” Circulation: Arrhythmia and Electrophysiology 17 (2024): e012452.

[172] M. N. Sanz, L. Grimbert, M. Moulin, et al., “Inducible Cardiac-Specific Deletion of Sirt1 in Male Mice Reveals Progressive Cardiac Dysfunction and Sensitization of the Heart to Pressure Overload,” International Journal of Molecular Sciences 20 (2019): 5005.

[173] R. R. Alcendor, S. Gao, P. Zhai, et al., “Sirt1 Regulates Aging and Resistance to Oxidative Stress in the Heart,” Circulation Research 100 (2007): 1512–1521.

[174] J. Pires Da Silva, K. Monceaux, and A. Guilbert, “Sirt1 Protects the Heart From Er Stress-Induced Injury by Promoting Eef2k/Eef2-Dependent Autophagy,” Cells 9 (2020): 426.

[175] A. Benigni, P. Cassis, S. Conti, et al., “Sirt3 Deficiency Shortens Life Span and Impairs Cardiac Mitochondrial Function Rescued by Opa1 Gene Transfer,” Antioxid Redox Signaling 31 (2019): 1255–1271.

[176] C. Koentges, K. Pfeil, T. Schnick, et al., “Sirt3 Deficiency Impairs Mitochondrial and Contractile Function in the Heart,” Basic Research in Cardiology 110 (2015): 36.

[177] M. Zhang, J. Wu, R. Sun, et al., “Sirt5 Deficiency Suppresses Mitochondrial Atp Production and Promotes Ampk Activation in Response to Energy Stress,” PLoS ONE 14 (2019): e0211796.

[178] T. Chen, J. Li, J. Liu, et al., “Activation of Sirt3 by Resveratrol Ameliorates Cardiac Fibrosis and Improves Cardiac Function via the Tgf-Beta/Smad3 Pathway,” American Journal of Physiology. Heart and Circulatory Physiology 308 (2015): H424–H434.

[179] A. Planavila, E. Dominguez, M. Navarro, et al., “Dilated Cardiomyopathy and Mitochondrial Dysfunction in Sirt1-Deficient Mice: A Role for Sirt1-Mef2 in Adult Heart,” Journal of Molecular and Cellular Cardiology 53 (2012): 521–531.

[180] M. Sarikhani, S. Maity, S. Mishra, et al., “Sirt2 Deacetylase Represses Nfat Transcription Factor to Maintain Cardiac Homeostasis,” Journal of Biological Chemistry 293 (2018): 5281–5294.

[181] Y. Zhao, Z. Lu, H. Zhang, et al., “Sodium-Glucose Exchanger 2 Inhibitor Canagliflozin Promotes Mitochondrial Metabolism and Alleviates Salt-Induced Cardiac Hypertrophy via Preserving Sirt3 Expression,” Journal of Advanced Research 70 (2025): 255–269.

[182] N. R. Sundaresan, P. Vasudevan, L. Zhong, et al., “The Sirtuin Sirt6 Blocks Igf-Akt Signaling and Development of Cardiac Hypertrophy by Targeting C-Jun,” Nature Medicine 18 (2012): 1643–1650.

[183] S. Yamamura, Y. Izumiya, S. Araki, et al., “Cardiomyocyte Sirt (Sirtuin) 7 Ameliorates Stress-Induced Cardiac Hypertrophy by Interacting With and Deacetylating Gata4,” Hypertension 75 (2020): 98–108.

[184] L. Wang, N. Quan, W. Sun, et al., “Cardiomyocyte-Specific Deletion of Sirt1 Gene Sensitizes Myocardium to Ischaemia and Reperfusion Injury,” Cardiovascular Research 114 (2018): 805–821.

[185] T. Yamamoto, K. Tamaki, K. Shirakawa, et al., “Cardiac Sirt1 Mediates the Cardioprotective Effect of Caloric Restriction by Suppressing Local Complement System Activation After Ischemia-Reperfusion,” American Journal of Physiology. Heart and Circulatory Physiology 310 (2016): H1003–H1014.

[186] X. He, H. Zeng, and J. X. Chen, “Ablation of Sirt3 Causes Coronary Microvascular Dysfunction and Impairs Cardiac Recovery post Myocardial Ischemia,” International Journal of Cardiology 215 (2016): 349–357.

[187] T. Bochaton, C. Crola-Da-Silva, B. Pillot, et al., “Inhibition of Myocardial Reperfusion Injury by Ischemic Postconditioning Requires Sirtuin 3-Mediated Deacetylation of Cyclophilin D,” Journal of Molecular and Cellular Cardiology 84 (2015): 61–69.

[188] B. Zhou, M. Xiao, H. Hu, et al., “Cardioprotective Role of Sirt5 in Response to Acute Ischemia Through a Novel Liver-Cardiac Crosstalk Mechanism,” Frontiers in Cell and Developmental Biology 9 (2021): 687559.

[189] P. A. Gorski, S. P. Jang, D. Jeong, et al., “Role of Sirt1 in Modulating Acetylation of the Sarco-Endoplasmic Reticulum Ca(2+)-Atpase in Heart Failure,” Circulation Research 124 (2019): e63–e80.

[190] A. C. Cantrell, J. Besanson, Q. Williams, et al., “Ferrostatin-1 Specifically Targets Mitochondrial Iron-Sulfur Clusters and Aconitase to Improve Cardiac Function in Sirtuin 3 Cardiomyocyte Knockout Mice,” Journal of Molecular and Cellular Cardiology 192 (2024): 36–47.

[191] Y. Hu, Y. Zheng, C. Liu, et al., “Mitochondrial Mof Regulates Energy Metabolism in Heart Failure via Atp5b Hyperacetylation,” Cell reports 43 (2024): 114839.

[192] K. Qian, J. Tang, Y. J. Ling, et al., “Exogenous Nadph Exerts a Positive Inotropic Effect and Enhances Energy Metabolism via Sirt3 in Pathological Cardiac Hypertrophy and Heart Failure,” EBioMedicine 98 (2023): 104863.

[193] D. R. Machin, Y. Auduong, V. R. Gogulamudi, et al., “Lifelong Sirt-1 Overexpression Attenuates Large Artery Stiffening With Advancing Age,” Aging (Albany NY) 12 (2020): 11314–11324.

[194] S. Stein, C. Lohmann, N. Schafer, et al., “Sirt1 Decreases Lox-1-Mediated Foam Cell Formation in Atherogenesis,” European Heart Journal 31 (2010): 2301–2309.

[195] L. Wen, Z. Chen, F. Zhang, et al., “Ca2+/Calmodulin-Dependent Protein Kinase Kinase Beta Phosphorylation of Sirtuin 1 in Endothelium Is Atheroprotective,” PNAS 110 (2013): E2420–E2427.

[196] Q. J. Zhang, Z. Wang, H. Z. Chen, et al., “Endothelium-Specific Overexpression of Class Iii Deacetylase Sirt1 Decreases Atherosclerosis in Apolipoprotein E-Deficient Mice,” Cardiovascular Research 80 (2008): 191–199.

[197] B. Bai, Y. Liang, C. Xu, et al., “Cyclin-Dependent Kinase 5-Mediated Hyperphosphorylation of Sirtuin-1 Contributes to the Development of Endothelial Senescence and Atherosclerosis,” Circulation 126 (2012): 729–740.

[198] Y. Zhang, X. Wang, X. K. Li, et al., “Sirtuin 2 Deficiency Aggravates Ageing-Induced Vascular Remodelling in Humans and Mice,” European Heart Journal 44 (2023): 2746–2759.

[199] L. Liberale, D. S. Gaul, A. Akhmedov, et al., “Endothelial Sirt6 Blunts Stroke Size and Neurological Deficit by Preserving Blood-Brain Barrier Integrity: A Translational Study,” European Heart Journal 41 (2020): 1575–1587.

[200] O. H. Lee, Y. M. Woo, S. Moon, et al., “Sirtuin 6 Deficiency Induces Endothelial Cell Senescence via Downregulation of Forkhead Box M1 Expression,” Aging (Albany NY) 12 (2020): 20946–20967.

[201] Z. Jin, Y. Xiao, F. Yao, et al., “Sirt6 Inhibits Cholesterol Crystal-Induced Vascular Endothelial Dysfunction via Nrf2 Activation,” Experimental Cell Research 387 (2020): 111744.

[202] Y. He, G. Yang, L. Sun, et al., “Sirt6 Inhibits Inflammatory Response Through Regulation of Nrf2 in Vascular Endothelial Cells,” International Immunopharmacology 99 (2021): 107926.

[203] J. L. Fry, Y. Shiraishi, R. Turcotte, et al., “Vascular Smooth Muscle Sirtuin-1 Protects Against Aortic Dissection during Angiotensin Ii-Induced Hypertension,” Journal of the American Heart Association 4 (2015): e002384.

[204] P. Gao, T. T. Xu, J. Lu, et al., “Overexpression of Sirt1 in Vascular Smooth Muscle Cells Attenuates Angiotensin Ii-Induced Vascular Remodeling and Hypertension in Mice,” Journal of Molecular Medicine (Berlin) 92 (2014): 347–357.

[205] T. Wei, G. Huang, J. Gao, et al., “Sirtuin 3 Deficiency Accelerates Hypertensive Cardiac Remodeling by Impairing Angiogenesis,” Journal of the American Heart Association 6 (2017): e006114.

[206] C. Zhang, N. Li, M. Suo, et al., “Sirtuin 3 Deficiency Aggravates Angiotensin Ii-Induced Hypertensive Cardiac Injury by the Impairment of Lymphangiogenesis,” Journal of Cellular and Molecular Medicine 25 (2021): 7760–7771.

[207] L. Yang, X. Wu, S. Bian, et al., “Sirt6-Mediated Vascular Smooth Muscle Cells Senescence Participates in the Pathogenesis of Abdominal Aortic Aneurysm,” Atherosclerosis 392 (2024): 117483.

[208] X. Li, S. Zhang, G. Blander, et al., “Sirt1 Deacetylates and Positively Regulates the Nuclear Receptor Lxr,” Molecular Cell 28 (2007): 91–106.

[209] J. Guo, Z. Wang, J. Wu, et al., “Endothelial Sirt6 Is Vital to Prevent Hypertension and Associated Cardiorenal Injury Through Targeting Nkx3.2-Gata5 Signaling,” Circulation Research 124 (2019): 1448–1461.

[210] Y. N. Ding, T. T. Wang, S. J. Lv, et al., “Sirt6 Is an Epigenetic Repressor of Thoracic Aortic Aneurysms via Inhibiting Inflammation and Senescence,” Signal Transduction and Targeted Therapy 8 (2023): 255.

[211] X. T. Yu, N. Zhao, Y. T. Ma, et al., “Sirtuin 6 Mitigates Thoracic Aortic Aneurysm Progression via Maintenance of Mitochondria Homeostasis in Vascular Smooth Muscle Cells,” Acta Pharmacologica Sinica 47 (2026): 103–118.

[212] M. Potente, L. Ghaeni, D. Baldessari, et al., “Sirt1 Controls Endothelial Angiogenic Functions during Vascular Growth,” Genes & development 21 (2007): 2644–2658.

[213] S. Zhou, H. Z. Chen, Y. Z. Wan, et al., “Repression of P66shc Expression by Sirt1 Contributes to the Prevention of Hyperglycemia-Induced Endothelial Dysfunction,” Circulation Research 109 (2011): 639–648.

[214] R. Bulvik, R. Breuer, M. Dvir-Ginzberg, et al., “Sirt1 Deficiency, Specifically in Fibroblasts, Decreases Apoptosis Resistance and Is Associated With Resolution of Lung-Fibrosis,” Biomolecules 10 (2020): 996.

[215] J. W. Hwang, S. Chung, I. K. Sundar, et al., “Cigarette Smoke-Induced Autophagy Is Regulated by Sirt1-Parp-1-Dependent Mechanism: Implication in Pathogenesis of Copd,” Archives of Biochemistry and Biophysics 500 (2010): 203–209.

[216] H. Yao, S. Chung, J. W. Hwang, et al., “Sirt1 Protects Against Emphysema via Foxo3-Mediated Reduction of Premature Senescence in Mice,” Journal of Clinical Investigation 122 (2012): 2032–2045.

[217] C. Y. Cheng, N. M. Gutierrez, M. B. Marzuki, et al., “Host Sirtuin 1 Regulates Mycobacterial Immunopathogenesis and Represents a Therapeutic Target Against Tuberculosis,” Science Immunology 2 (2017): eaaj1789.

[218] J. Wang, W. Li, F. Zhao, et al., “Sirt3 Regulates Nlrp3 and Participates in the Effects of Plantainoside D on Acute Lung Injury Sepsis,” Aging (Albany NY) 15 (2023): 6710–6720.

[219] K. Peng, Y. X. Yao, X. Lu, et al., “Mitochondrial Dysfunction-Associated Alveolar Epithelial Senescence Is Involved in Cdcl(2)-Induced Copd-Like Lung Injury,” Journal of Hazardous Materials 476 (2024): 135103.

[220] Y. Li, K. Wong, A. Giles, et al., “Hepatic Sirt1 Attenuates Hepatic Steatosis and Controls Energy Balance in Mice by Inducing Fibroblast Growth Factor 21,” Gastroenterology 146 (2014): 539–549 e7.

[221] S. Park, M. J. Chung, J. Y. Son, et al., “The Role of Sirtuin 2 in Sustaining Functional Integrity of the Liver,” Life Sciences 285 (2021): 119997.

[222] P. G. Lankisch, H. Buschmann-Kaspari, J. Otto, et al., “Correlation of Pancreatic Enzyme Levels With the Patient's Recovery From Acute Edematous Pancreatitis,” Klinische Wochenschrift 68 (1990): 565–569.

[223] F. K. Huynh, X. Hu, Z. Lin, et al., “Loss of Sirtuin 4 Leads to Elevated Glucose- and Leucine-Stimulated Insulin Levels and Accelerated Age-Induced Insulin Resistance in Multiple Murine Genetic Backgrounds,” Journal of Inherited Metabolic Disease 41 (2018): 59–72.

[224] J. Park, Y. Chen, D. X. Tishkoff, et al., “Sirt5-Mediated Lysine Desuccinylation Impacts Diverse Metabolic Pathways,” Molecular Cell 50 (2013): 919–930.

[225] E. S. Goetzman, S. S. Bharathi, Y. Zhang, et al., “Impaired Mitochondrial Medium-Chain Fatty Acid Oxidation Drives Periportal Macrovesicular Steatosis in Sirtuin-5 Knockout Mice,” Scientific Reports 10 (2020): 18367.

[226] T. Hou, Y. Tian, Z. Cao, et al., “Cytoplasmic Sirt6-Mediated Acsl5 Deacetylation Impedes Nonalcoholic Fatty Liver Disease by Facilitating Hepatic Fatty Acid Oxidation,” Molecular Cell 82 (2022): 4099–4115 e9.

[227] F. Li, L. Zhang, H. Xue, et al., “Sirt1 Alleviates Hepatic Ischemia-Reperfusion Injury via the Mir-182-Mediated Xbp1/Nlrp3 Pathway,” Molecular Therapy Nucleic Acids 23 (2021): 1066–1077.

[228] X. Cui, Q. Chen, Z. Dong, et al., “Inactivation of Sirt1 in Mouse Livers Protects Against Endotoxemic Liver Injury by Acetylating and Activating Nf-Kappab,” Cell death & disease 7 (2016): e2403.

[229] J. Wang, H. W. Koh, L. Zhou, et al., “Sirtuin 2 Aggravates Postischemic Liver Injury by Deacetylating Mitogen-Activated Protein Kinase Phosphatase-1,” Hepatology 65 (2017): 225–236.

[230] L. Hao, I. H. Bang, J. Wang, et al., “Errgamma Suppression by Sirt6 Alleviates Cholestatic Liver Injury and Fibrosis,” JCI Insight 5 (2020): e137566.

[231] C. Ding, B. Liu, T. Yu, et al., “Sirt7 Protects Against Liver Fibrosis by Suppressing Stellate Cell Activation via Tgf-Beta/Smad2/3 Pathway,” Biomedicine & Pharmacotherapy 180 (2024): 117477.

[232] X. Liu, Y. Song, M. Shen, et al., “Smooth Muscle Silent Information Regulator 1 Contributes to Colitis in Mice,” International Journal of Molecular Sciences 26 (2025): 1807.

[233] L. Wang, J. Li, M. Jiang, et al., “Sirt1 Stabilizes Beta-Trcp1 to Inhibit Snail1 Expression in Maintaining Intestinal Epithelial Integrity to Alleviate Colitis,” Cell Mol Gastroenterol Hepatol 18 (2024): 101354.

[234] C. Li, Y. Zhou, P. Rychahou, et al., “Sirt2 Contributes to the Regulation of Intestinal Cell Proliferation and Differentiation,” Cellular and Molecular Gastroenterology and Hepatology 10 (2020): 43–57.

[235] F. Liu, H. F. Bu, H. Geng, et al., “Sirtuin-6 Preserves R-Spondin-1 Expression and Increases Resistance of Intestinal Epithelium to Injury in Mice,” Molecular Medicine 23 (2017): 272–284.

[236] X. Su, L. Zhao, H. Zhang, et al., “Sirtuin 6 Inhibits Group 3 Innate Lymphoid Cell Function and Gut Immunity by Suppressing Il-22 Production,” Frontiers in immunology 15 (2024): 1402834.

[237] Q. Zhang, P. Zhang, G. J. Qi, et al., “Cdk5 Suppression Blocks Sirt1 Degradation via the Ubiquitin-Proteasome Pathway in Parkinson's Disease Models,” Biochimica et Biophysica Acta (BBA) - General Subjects 1862 (2018): 1443–1451.

[238] L. Liu, A. Arun, L. Ellis, et al., “Sirt2 Enhances 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (Mptp)-Induced Nigrostriatal Damage via Apoptotic Pathway,” Frontiers in aging neuroscience 6 (2014): 184.

[239] E. M. Szego, E. Gerhardt, and T. F. Outeiro, “Sirtuin 2 Enhances Dopaminergic Differentiation via the Akt/Gsk-3beta/Beta-Catenin Pathway,” Neurobiology of Aging 56 (2017): 7–16.

[240] J. Yan, P. Zhang, J. Tan, et al., “Cdk5 Phosphorylation-Induced Sirt2 Nuclear Translocation Promotes the Death of Dopaminergic Neurons in Parkinson's Disease,” Npj Parkinson's Disease 8 (2022): 46.

[241] X. Zhang, X. Ren, Q. Zhang, et al., “Pgc-1alpha/Erralpha-Sirt3 Pathway Regulates Daergic Neuronal Death by Directly Deacetylating Sod2 and Atp Synthase Beta,” Antioxid Redox Signaling 24 (2016): 312–328.

[242] H. Shi, H. X. Deng, D. Gius, et al., “Sirt3 Protects Dopaminergic Neurons From Mitochondrial Oxidative Stress,” Human Molecular Genetics 26 (2017): 1915–1926.

[243] L. Liu, C. Peritore, J. Ginsberg, et al., “Protective Role of Sirt5 Against Motor Deficit and Dopaminergic Degeneration in Mptp-Induced Mice Model of Parkinson's Disease,” Behavioural Brain Research 281 (2015): 215–221.

[244] S. Michan, Y. Li, M. M. Chou, et al., “Sirt1 Is Essential for Normal Cognitive Function and Synaptic Plasticity,” Journal of Neuroscience 30 (2010): 9695–9707.

[245] N. Bai, N. Li, R. Cheng, et al., “Inhibition of Sirt2 Promotes App Acetylation and Ameliorates Cognitive Impairment in App/Ps1 Transgenic Mice,” Cell reports 40 (2022): 111062.

[246] A. Cheng, J. Wang, N. Ghena, et al., “Sirt3 Haploinsufficiency Aggravates Loss of Gabaergic Interneurons and Neuronal Network Hyperexcitability in an Alzheimer's Disease Model,” Journal of Neuroscience 40 (2020): 694–709.

[247] M. Jiang, J. Wang, J. Fu, et al., “Neuroprotective Role of Sirt1 in Mammalian Models of Huntington's Disease Through Activation of Multiple Sirt1 Targets,” Nature Medicine 18 (2011): 153–158.

[248] A. Bobrowska, G. Donmez, A. Weiss, et al., “Sirt2 Ablation Has no Effect on Tubulin Acetylation in Brain, Cholesterol Biosynthesis or the Progression of Huntington's Disease Phenotypes in Vivo,” PLoS ONE 7 (2012): e34805.

[249] Y. Lei, J. Wang, D. Wang, et al., “Sirt1 in Forebrain Excitatory Neurons Produces Sexually Dimorphic Effects on Depression-Related Behaviors and Modulates Neuronal Excitability and Synaptic Transmission in the Medial Prefrontal Cortex,” Molecular Psychiatry 25 (2020): 1094–1111.

[250] Z. Zhang, P. Zhang, G. J. Qi, et al., “Cdk5-Mediated Phosphorylation of Sirt2 Contributes to Depressive-Like Behavior Induced by Social Defeat Stress,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1864 (2018): 533–541.

[251] K. Hu, H. Chen, Y. Gao, et al., “Astrocytic Sirt6 Is a Potential Anti-Depression and Anti-Anxiety Target,” Progress in Neuro-Psychopharmacology & Biological Psychiatry 123 (2023): 110702.

[252] S. Libert, K. Pointer, E. L. Bell, et al., “Sirt1 Activates Mao-a in the Brain to Mediate Anxiety and Exploratory Drive,” Cell 147 (2011): 1459–1472.

[253] H. D. Kim, J. Wei, T. Call, et al., “Sirt1 Coordinates Transcriptional Regulation of Neural Activity and Modulates Depression-Like Behaviors in the Nucleus Accumbens,” Biological Psychiatry 96 (2024): 495–505.

[254] A. Kwok, B. Chaqour, R. S. Khan, et al., “Pharmacological Activation and Transgenic Overexpression of Sirt1 Attenuate Traumatic Optic Neuropathy Induced by Blunt Head Impact,” Translational Vision Science & Technology 13 (2024): 27.

[255] Y. Ge, X. Wu, Y. Cai, et al., “Fndc5 Prevents Oxidative Stress and Neuronal Apoptosis After Traumatic Brain Injury Through Sirt3-Dependent Regulation of Mitochondrial Quality Control,” Cell Death & Disease 15 (2024): 364.

[256] J. Guo, J. Nie, D. Li, et al., “The Role of Nad-Dependent Deacetylase Sirtuin-2 in Liver Metabolic Stress Through Regulating Pyruvate Kinase M2 Ubiquitination,” Journal of translational medicine 22 (2024): 656.

[257] E. Zaganjor, H. Yoon, J. B. Spinelli, et al., “Sirt4 Is an Early Regulator of Branched-Chain Amino Acid Catabolism That Promotes Adipogenesis,” Cell reports 36 (2021): 109345.

[258] W. Wang, J. Liang, Y. Zhang, et al., “Myeloid Sirtuin 6 Deficiency Causes Obesity in Mice by Inducing Norepinephrine Degradation to Limit Thermogenic Tissue Function,” Science signaling 18 (2025): eadl6441.

[259] X. Cui, L. Yao, X. Yang, et al., “Sirt6 Regulates Metabolic Homeostasis in Skeletal Muscle Through Activation of Ampk,” American Journal of Physiology. Endocrinology and Metabolism 313 (2017): E493–E505.

[260] T. Mizumoto, T. Yoshizawa, Y. Sato, et al., “Sirt7 Deficiency Protects Against Aging-Associated Glucose Intolerance and Extends Lifespan in Male Mice,” Cells 11 (2022): 3609.

[261] T. Yoshizawa, Y. Sato, S. U. Sobuz, et al., “Sirt7 Suppresses Energy Expenditure and Thermogenesis by Regulating Brown Adipose Tissue Functions in Mice,” Nature Communications 13 (2022): 7439.

[262] A. Purushotham, T. T. Schug, Q. Xu, et al., “Hepatocyte-Specific Deletion of Sirt1 Alters Fatty Acid Metabolism and Results in Hepatic Steatosis and Inflammation,” Cell metabolism 9 (2009): 327–338.

[263] M. D. Hirschey, T. Shimazu, E. Goetzman, et al., “Sirt3 Regulates Mitochondrial Fatty-Acid Oxidation by Reversible Enzyme Deacetylation,” Nature 464 (2010): 121–125.

[264] Y. Guan, S. R. Wang, X. Z. Huang, et al., “Nicotinamide Mononucleotide, an Nad(+) Precursor, Rescues Age-Associated Susceptibility to Aki in a Sirtuin 1-Dependent Manner,” Journal of the American Society of Nephrology 28 (2017): 2337–2352.

[265] Y. J. Jung, A. S. Lee, T. Nguyen-Thanh, et al., “Sirt2 Regulates Lps-Induced Renal Tubular Cxcl2 and Ccl2 Expression,” Journal of the American Society of Nephrology 26 (2015): 1549–1560.

[266] L. Shen, Q. Zhang, S. Tu, et al., “Sirt3 Mediates Mitofusin 2 Ubiquitination and Degradation to Suppress Ischemia Reperfusion-Induced Acute Kidney Injury,” Experimental Cell Research 408 (2021): 112861.

[267] W. Y. Zhao, L. Zhang, M. X. Sui, et al., “Protective Effects of Sirtuin 3 in a Murine Model of Sepsis-Induced Acute Kidney Injury,” Scientific Reports 6 (2016): 33201.

[268] Y. Jian, Y. Yang, L. Cheng, et al., “Sirt3 Mitigates Lps-Induced Mitochondrial Damage in Renal Tubular Epithelial Cells by Deacetylating Yme1l1,” Cell Proliferation 56 (2023): e13362.

[269] L. Perico, M. Morigi, C. Rota, et al., “Human Mesenchymal Stromal Cells Transplanted Into Mice Stimulate Renal Tubular Cells and Enhance Mitochondrial Function,” Nature Communications 8 (2017): 983.

[270] T. Chiba, K. D. Peasley, K. R. Cargill, et al., “Sirtuin 5 Regulates Proximal Tubule Fatty Acid Oxidation to Protect Against Aki,” Journal of the American Society of Nephrology 30 (2019): 2384–2398.

[271] K. Hasegawa, S. Wakino, P. Simic, et al., “Renal Tubular Sirt1 Attenuates Diabetic Albuminuria by Epigenetically Suppressing Claudin-1 Overexpression in Podocytes,” Nature Medicine 19 (2013): 1496–1504.

[272] P. Y. Chuang, W. Cai, X. Li, et al., “Reduction in Podocyte Sirt1 Accelerates Kidney Injury in Aging Mice,” American Journal of Physiology. Renal Physiology 313 (2017): F621–F628.

[273] R. Vasko, S. Xavier, J. Chen, et al., “Endothelial Sirtuin 1 Deficiency Perpetrates Nephrosclerosis Through Downregulation of Matrix Metalloproteinase-14: Relevance to Fibrosis of Vascular Senescence,” Journal of the American Society of Nephrology 25 (2014): 276–291.

[274] Q. Yang, J. Hu, Y. Yang, et al., “Sirt6 Deficiency Aggravates Angiotensin Ii-Induced Cholesterol Accumulation and Injury in Podocytes,” Theranostics 10 (2020): 7465–7479.

[275] W. Li, W. Feng, X. Su, et al., “Sirt6 Protects Vascular Smooth Muscle Cells From Osteogenic Transdifferentiation via Runx2 in Chronic Kidney Disease,” Journal of Clinical Investigation 132 (2022): e150051.

[276] L. Xiong, X. Ye, Z. Chen, et al., “Advanced Maternal Age-Associated Sirt1 Deficiency Compromises Trophoblast Epithelial-Mesenchymal Transition Through an Increase in Vimentin Acetylation,” Aging Cell 20 (2021): e13491.

[277] C. Liu, Z. Song, L. Wang, et al., “Sirt1 Regulates Acrosome Biogenesis by Modulating Autophagic Flux during Spermiogenesis in Mice,” Development 144 (2017): 441–451.

[278] K. Arul Nambi Rajan, M. Khater, F. Soncin, et al., “Sirtuin1 Is Required for Proper Trophoblast Differentiation and Placental Development in Mice,” Placenta 62 (2018): 1–8.

[279] H. Li, G. K. Rajendran, N. Liu, et al., “Sirt1 Modulates the Estrogen-Insulin-Like Growth Factor-1 Signaling for Postnatal Development of Mammary Gland in Mice,” Breast Cancer Research 9 (2007): R1.

[280] J. D. Iljas and H. A. Homer, “Sirt3 Is Dispensable for Oocyte Quality and Female Fertility in Lean and Obese Mice,” Faseb Journal 34 (2020): 6641–6653.

[281] W. Sun, W. Qiao, B. Zhou, et al., “Overexpression of Sirt1 in Mesenchymal Stem Cells Protects Against Bone Loss in Mice by Foxo3a Deacetylation and Oxidative Stress Inhibition,” Metabolism 88 (2018): 61–71.

[282] X. Jin, X. Sun, X. Ma, et al., “Sirt1 Maintains Bone Homeostasis by Regulating Osteoblast Glycolysis Through Got1,” Cellular and Molecular Life Sciences 81 (2024): 204.

[283] H. Wang, Z. Hu, J. Wu, et al., “Sirt1 Promotes Osteogenic Differentiation and Increases Alveolar Bone Mass via Bmi1 Activation in Mice,” Journal of Bone and Mineral Research 34 (2019): 1169–1181.

[284] L. Louvet, D. Leterme, S. Delplace, et al., “Sirtuin 1 Deficiency Decreases Bone Mass and Increases Bone Marrow Adiposity in a Mouse Model of Chronic Energy Deficiency,” Bone 136 (2020): 115361.

[285] W. Ling, K. Krager, K. K. Richardson, et al., “Mitochondrial Sirt3 Contributes to the Bone Loss Caused by Aging or Estrogen Deficiency,” JCI Insight 6 (2021): e146728.

[286] K. K. Richardson, G. O. Adam, W. Ling, et al., “Mitochondrial Protein Deacetylation by Sirt3 in Osteoclasts Promotes Bone Resorption With Aging in Female Mice,” Molecular Metabolism 88 (2024): 102012.

[287] S. J. Kim, Y. Piao, M. G. Lee, et al., “Loss of Sirtuin 6 in Osteoblast Lineage Cells Activates Osteoclasts, Resulting in Osteopenia,” Bone 138 (2020): 115497.

[288] Y. J. Moon, Z. Zhang, I. H. Bang, et al., “Sirtuin 6 in Preosteoclasts Suppresses Age- and Estrogen Deficiency-Related Bone Loss by Stabilizing Estrogen Receptor Alpha,” Cell Death and Differentiation 26 (2019): 2358–2370.

[289] J. Elayyan, I. Carmon, L. Zecharyahu, et al., “Lef1 Ablation Alleviates Cartilage Mineralization Following Posttraumatic Osteoarthritis Induction,” PNAS 119 (2022): e2116855119.

[290] O. Gabay, C. Sanchez, M. Dvir-Ginzberg, et al., “Sirtuin 1 Enzymatic Activity Is Required for Cartilage Homeostasis in Vivo in a Mouse Model,” Arthritis and Rheumatism 65 (2013): 159–166.

[291] A. K. Snyder-Warwick, A. Satoh, K. B. Santosa, et al., “Hypothalamic Sirt1 Protects Terminal Schwann Cells and Neuromuscular Junctions From Age-Related Morphological Changes,” Aging Cell 17 (2018): e12776.

[292] M. J. Myers, D. L. Shepherd, A. J. Durr, et al., “The Role of Sirt1 in Skeletal Muscle Function and Repair of Older Mice,” Journal of Cachexia, Sarcopenia and Muscle 10 (2019): 929–949.

[293] S. A. Samant, A. Kanwal, V. B. Pillai, et al., “The Histone Deacetylase Sirt6 Blocks Myostatin Expression and Development of Muscle Atrophy,” Scientific Reports 7 (2017): 11877.

[294] C. Jiang, J. Liu, M. Guo, et al., “The Nad-Dependent Deacetylase Sirt2 Regulates T Cell Differentiation Involved in Tumor Immune Response,” International Journal of Biological Sciences 16 (2020): 3075–3084.

[295] Y. L. N. Abril, I. R. Fernandez, J. Y. Hong, et al., “Pharmacological and Genetic Perturbation Establish Sirt5 as a Promising Target in Breast Cancer,” Oncogene 40 (2021): 1644–1658.

[296] M. Xie, M. Liu, and C. S. He, “Sirt1 Regulates Endothelial Notch Signaling in Lung Cancer,” PLoS ONE 7 (2012): e45331.

[297] P. Qiu, W. Hou, H. Wang, et al., “Sirt1 Deficiency Upregulates Glutathione Metabolism to Prevent Hepatocellular Carcinoma Initiation in Mice,” Oncogene 40 (2021): 6023–6033.

[298] A. V. Pinho, A. Mawson, A. Gill, et al., “Sirtuin 1 Stimulates the Proliferation and the Expression of Glycolysis Genes in Pancreatic Neoplastic Lesions,” Oncotarget 7 (2016): 74768–74778.

[299] W. Giblin, L. Bringman-Rodenbarger, A. H. Guo, et al., “The Deacylase Sirt5 Supports Melanoma Viability by Influencing Chromatin Dynamics,” Journal of Clinical Investigation 131 (2021): e138926.

[300] F. Wang, Z. Li, J. Zhou, et al., “Sirt1 Regulates the Phosphorylation and Degradation of P27 by Deacetylating Cdk2 to Promote T-Cell Acute Lymphoblastic Leukemia Progression,” Journal of Experimental & Clinical Cancer Research 40 (2021): 259.

[301] A. Abraham, S. Qiu, B. K. Chacko, et al., “Sirt1 Regulates Metabolism and Leukemogenic Potential in Cml Stem Cells,” Journal of Clinical Investigation 129 (2019): 2685–2701.

[302] M. Li, Y. L. Chiang, C. A. Lyssiotis, et al., “Non-Oncogene Addiction to Sirt3 Plays a Critical Role in Lymphomagenesis,” Cancer Cell 35 (2019): 916–931 e9.

[303] H. Yang, S. M. Lee, B. Gao, et al., “Histone Deacetylase Sirtuin 1 Deacetylates Irf1 Protein and Programs Dendritic Cells to Control Th17 Protein Differentiation during Autoimmune Inflammation,” Journal of Biological Chemistry 288 (2013): 37256–37266.

[304] W. Zhang, D. Xiao, X. Li, et al., “Sirt1 Inactivation Switches Reactive Astrocytes to an Antiinflammatory Phenotype in Cns Autoimmunity,” Journal of Clinical Investigation 132 (2022): e151803.

[305] H. W. Lim, S. G. Kang, J. K. Ryu, et al., “Sirt1 Deacetylates Rorgammat and Enhances Th17 Cell Generation,” Journal of Experimental Medicine 212 (2015): 607–617.

[306] R. Hisada, N. Yoshida, M. Umeda, et al., “The Deacetylase Sirt2 Contributes to Autoimmune Disease Pathogenesis by Modulating Il-17a and Il-2 Transcription,” Cellular & Molecular Immunology 19 (2022): 738–750.

[307] A. Daenthanasanmak, S. Iamsawat, P. Chakraborty, et al., “Targeting Sirt-1 Controls Gvhd by Inhibiting T-Cell Allo-Response and Promoting Treg Stability in Mice,” Blood 133 (2019): 266–279.

[308] T. Toubai, H. Tamaki, D. C. Peltier, et al., “Mitochondrial Deacetylase Sirt3 Plays an Important Role in Donor T Cell Responses After Experimental Allogeneic Hematopoietic Transplantation,” Journal of Immunology 201 (2018): 3443–3455.

[309] E. Ciarlo, T. Heinonen, C. Theroude, et al., “Sirtuin 2 Deficiency Increases Bacterial Phagocytosis by Macrophages and Protects From Chronic Staphylococcal Infection,” Frontiers in Immunology 8 (2017): 1037.

[310] H. A. Eskandarian, F. Impens, M. A. Nahori, et al., “A Role for Sirt2-Dependent Histone H3k18 Deacetylation in Bacterial Infection,” Science 341 (2013): 1238858.

[311] T. F. Liu, V. Vachharajani, P. Millet, et al., “Sequential Actions of Sirt1-Relb-Sirt3 Coordinate Nuclear-Mitochondrial Communication during Immunometabolic Adaptation to Acute Inflammation and Sepsis,” Journal of Biological Chemistry 290 (2015): 396–408.

[312] T. S. Kim, Y. B. Jin, Y. S. Kim, et al., “Sirt3 Promotes Antimycobacterial Defenses by Coordinating Mitochondrial and Autophagic Functions,” Autophagy 15 (2019): 1356–1375.

[313] A. Papi, C. Brightling, S. E. Pedersen, et al., “Asthma,” Lancet 391 (2018): 783–800.

[314] M. S. Taylor, R. R. Chivukula, L. C. Myers, et al., “Delayed Alveolar Epithelialization: A Distinct Pathology in Diffuse Acute Lung Injury,” American Journal of Respiratory and Critical Care Medicine 197 (2018): 522–524.

[315] S. Li, G. Zhao, L. Chen, et al., “Resveratrol Protects Mice From Paraquat-Induced Lung Injury: The Important Role of Sirt1 and Nrf2 Antioxidant Pathways,” Molecular Medicine Reports 13 (2016): 1833–1838.

[316] Z. N. Liu, M. Zhao, Q. Zheng, et al., “Inhibitory Effects of Rosiglitazone on Paraquat-Induced Acute Lung Injury in Rats,” Acta Pharmacologica Sinica 34 (2013): 1317–1324.

[317] K. C. Lee, P. S. Wu, and H. C. Lin, “Pathogenesis and Treatment of Non-Alcoholic Steatohepatitis and Its Fibrosis,” Clinical and Molecular Hepatology 29 (2023): 77–98.

[318] S. H. Ibrahim, R. Kohli, and G. J. Gores, “Mechanisms of Lipotoxicity in Nafld and Clinical Implications,” Journal of Pediatric Gastroenterology and Nutrition 53 (2011): 131–140.

[319] X. Ma, T. Huang, X. Chen, et al., “Molecular Mechanisms in Liver Repair and Regeneration: From Physiology to Therapeutics,” Signal Transduction and Targeted Therapy 10 (2025): 63.

[320] S. W. French, “Chronic Alcohol Binging Injures the Liver and Other Organs by Reducing Nad(+) Levels Required for Sirtuin's Deacetylase Activity,” Experimental and Molecular Pathology 100 (2016): 303–306.

[321] M. You, A. Jogasuria, C. Taylor, et al., “Sirtuin 1 Signaling and Alcoholic Fatty Liver Disease,” Hepatobiliary Surgery and Nutrition 4 (2015): 88–100.

[322] S. Sedda, E. Franze, G. Bevivino, et al., “Reciprocal Regulation Between Smad7 and Sirt1 in the Gut,” Frontiers in immunology 9 (2018): 1854.

[323] Y. Ko, R. Butcher, and R. W. Leong, “Epidemiological Studies of Migration and Environmental Risk Factors in the Inflammatory Bowel Diseases,” World Journal of Gastroenterology 20 (2014): 1238–1247.

[324] E. V. Loftus, Jr., “Clinical Epidemiology of Inflammatory Bowel Disease: Incidence, Prevalence, and Environmental Influences,” Gastroenterology 126 (2004): 1504–1517.

[325] E. De-Madaria, J. L. Buxbaum, P. Maisonneuve, et al., “Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis,” New England Journal of Medicine 387 (2022): 989–1000.

[326] Y. Luo, Z. Li, P. Ge, et al., “Comprehensive Mechanism, Novel Markers and Multidisciplinary Treatment of Severe Acute Pancreatitis-Associated Cardiac Injury—a Narrative Review,” Journal of Inflammation Research 14 (2021): 3145–3169.

[327] L. Gan, M. R. Cookson, L. Petrucelli, et al., “Converging Pathways in Neurodegeneration, From Genetics to Mechanisms,” Nature Neuroscience 21 (2018): 1300–1309.

[328] J. Xu, W. Du, Y. Zhao, et al., “Mitochondria Targeting Drugs for Neurodegenerative Diseases-Design, Mechanism and Application,” Acta Pharmaceutica Sinica B 12 (2022): 2778–2789.

[329] M. Jucker and L. C. Walker, “Propagation and Spread of Pathogenic Protein Assemblies in Neurodegenerative Diseases,” Nature Neuroscience 21 (2018): 1341–1349.

[330] C. Soto and S. Pritzkow, “Protein Misfolding, Aggregation, and Conformational Strains in Neurodegenerative Diseases,” Nature Neuroscience 21 (2018): 1332–1340.

[331] J. Lu, C. Wang, X. Cheng, et al., “A Breakdown in Microglial Metabolic Reprogramming Causes Internalization Dysfunction of Alpha-Synuclein in a Mouse Model of Parkinson's Disease,” Journal of Neuroinflammation 19 (2022): 113.

[332] C. Yang, Y. Mo, E. Xu, et al., “Astragaloside Iv Ameliorates Motor Deficits and Dopaminergic Neuron Degeneration via Inhibiting Neuroinflammation and Oxidative Stress in a Parkinson's Disease Mouse Model,” International Immunopharmacology 75 (2019): 105651.

[333] S. Sarkar, E. Malovic, D. S. Harishchandra, et al., “Mitochondrial Impairment in Microglia Amplifies Nlrp3 Inflammasome Proinflammatory Signaling in Cell Culture and Animal Models of Parkinson's Disease,” NPJ Parkinsons Disease 3 (2017): 30.

[334] E. C. Hirsch, S. Vyas, and S. Hunot, “Neuroinflammation in Parkinson's Disease,” Parkinsonism & Related Disorders 18, no. Suppl 1 (2012): S210–S212.

[335] L. Liu, C. Peritore, J. Ginsberg, et al., “Sirt3 Attenuates Mptp-Induced Nigrostriatal Degeneration via Enhancing Mitochondrial Antioxidant Capacity,” Neurochemical Research 40 (2015): 600–608.

[336] W. Yang, K. Nagasawa, C. Munch, et al., “Mitochondrial Sirtuin Network Reveals Dynamic Sirt3-Dependent Deacetylation in Response to Membrane Depolarization,” Cell 167 (2016): 985–1000 e21.

[337] J. Hardy and D. J. Selkoe, “The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics,” Science 297 (2002): 353–356.

[338] I. Benilova, E. Karran, and B. De Strooper, “The Toxic Abeta Oligomer and Alzheimer's Disease: An Emperor in Need of Clothes,” Nature Neuroscience 15 (2012): 349–357.

[339] J. Guo, J. Cheng, B. J. North, et al., “Functional Analyses of Major Cancer-Related Signaling Pathways in Alzheimer's Disease Etiology,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1868 (2017): 341–358.

[340] E. S. Jung, H. Choi, H. Song, et al., “P53-Dependent Sirt6 Expression Protects Abeta42-Induced DNA Damage,” Scientific Reports 6 (2016): 25628.

[341] N. Sadick, M. H. Kaplan, S. G. Pahwa, et al., “Unusual Features of Scabies Complicating Human T-Lymphotropic Virus Type Iii Infection,” Journal of the American Academy of Dermatology 15 (1986): 482–486.

[342] M. J. Dowie, E. L. Scotter, E. Molinari, et al., “The Therapeutic Potential of G-Protein Coupled Receptors in Huntington's Disease,” Pharmacology & Therapeutics 128 (2010): 305–323.

[343] A. Nair, A. Razi, S. Gregory, et al., “Imbalanced Basal Ganglia Connectivity Is Associated With Motor Deficits and Apathy in Huntington's Disease,” Brain 145 (2022): 991–1000.

[344] M. A. Soliman, F. Aboharb, N. Zeltner, et al., “Pluripotent Stem Cells in Neuropsychiatric Disorders,” Molecular Psychiatry 22 (2017): 1241–1249.

[345] K. K. Hui, R. Endo, A. Sawa, et al., “A Perspective on the Potential Involvement of Impaired Proteostasis in Neuropsychiatric Disorders,” Biological Psychiatry 91 (2022): 335–345.

[346] R. Horton, “Offline: Who's Hits and Misses for Mental Health,” Lancet 399 (2022): 2253.

[347] P. Hu, Y. Wang, X. H. Qi, et al., “Sirt1 in the Bnst Modulates Chronic Stress-Induced Anxiety of Male Mice via Fkbp5 and Corticotropin-Releasing Factor Signaling,” Molecular Psychiatry 28 (2023): 5101–5117.

[348] Z. Sun, S. Zhao, X. Suo, et al., “Sirt1 Protects Against Hippocampal Atrophy and Its Induced Cognitive Impairment in Middle-Aged Mice,” BMC Neuroscience [Electronic Resource] 23 (2022): 33.

[349] H. Guo, C. Deji, H. Peng, et al., “The Role of Sirt1 in the Basolateral Amygdala in Depression-Like Behaviors in Mice,” Genes, Brain, and Behavior 20 (2021): e12765.

[350] J. C. Jimenez, K. Su, A. R. Goldberg, et al., “Anxiety Cells in a Hippocampal-Hypothalamic Circuit,” Neuron 97 (2018): 670–683 e6.

[351] E. D. Leonardo and R. Hen, “Genetics of Affective and Anxiety Disorders,” Annual Review of Psychology 57 (2006): 117–137.

[352] W. Li, B. Guo, K. Tao, et al., “Inhibition of Sirt1 in Hippocampal Ca1 Ameliorates Ptsd-Like Behaviors in Mice by Protections of Neuronal Plasticity and Serotonin Homeostasis via Nhlh2/Mao-a Pathway,” Biochemical and Biophysical Research Communications 518 (2019): 344–350.

[353] C. Lopez-Otin, M. A. Blasco, L. Partridge, et al., “Hallmarks of Aging: An Expanding Universe,” Cell 186 (2023): 243–278.

[354] W. Tonnus, A. Belavgeni, F. Beuschlein, et al., “The Role of Regulated Necrosis in Endocrine Diseases,” Nature Reviews Endocrinology 17 (2021): 497–510.

[355] S. Dewanjee, J. Vallamkondu, R. S. Kalra, et al., “The Emerging Role of Hdacs: Pathology and Therapeutic Targets in Diabetes Mellitus,” Cells 10 (2021): 1340.

[356] S. Khosla, J. N. Farr, T. Tchkonia, et al., “The Role of Cellular Senescence in Ageing and Endocrine Disease,” Nature reviews Endocrinology 16 (2020): 263–275.

[357] I. Sturmlechner, M. Durik, C. J. Sieben, et al., “Cellular Senescence in Renal Ageing and Disease,” Nature Reviews Nephrology 13 (2017): 77–89.

[358] L. Guarente, “Sirtuins as Potential Targets for Metabolic Syndrome,” Nature 444 (2006): 868–874.

[359] American Diabetes Association. “(2) Classification and Diagnosis of Diabetes,” Diabetes Care 38, (2015): S8–S16.

[360] B. E. Harcourt, S. A. Penfold, and J. M. Forbes, “Coming Full Circle in Diabetes Mellitus: From Complications to Initiation,” Nature reviews Endocrinology 9 (2013): 113–123.

[361] J. S. Skyler, “Diabetes Mellitus: Pathogenesis and Treatment Strategies,” Journal of Medicinal Chemistry 47 (2004): 4113–4117.

[362] J. Song, B. Yang, X. Jia, et al., “Distinctive Roles of Sirtuins on Diabetes, Protective or Detrimental?,” Frontiers in Endocrinology (Lausanne) 9 (2018): 724.

[363] H. H. Liu and J. J. Li, “Aging and Dyslipidemia: A Review of Potential Mechanisms,” Ageing Research Reviews 19 (2015): 43–52.

[364] F. J. Felix-Redondo, M. Grau, and D. Fernandez-Berges, “Cholesterol and Cardiovascular Disease in the Elderly. Facts and Gaps,” Aging Disease 4 (2013): 154–169.

[365] P. Vazquez, C. Escalona-Garrido, N. Pescador, et al., “Sirtuin 1 Overexpression in Mice Preserves Insulin and Thermogenic Responses in Subcutaneous Inguinal White Adipose Tissue Under Proinflammatory Conditions,” Journal of Physiology and Biochemistry 81 (2025): 1019–1035.

[366] Y. Majeed, N. Halabi, A. Y. Madani, et al., “Sirt1 Promotes Lipid Metabolism and Mitochondrial Biogenesis in Adipocytes and Coordinates Adipogenesis by Targeting Key Enzymatic Pathways,” Scientific Reports 11 (2021): 8177.

[367] C. Escalona-Garrido, P. Vazquez, P. Mera, et al., “Moderate Sirt1 Overexpression Protects Against Brown Adipose Tissue Inflammation,” Molecular Metabolism 42 (2020): 101097.

[368] J. N. Curry and J. A. Mccormick, “Cisplatin-Induced Kidney Injury: Delivering the Goods,” Journal of the American Society of Nephrology 33 (2022): 255–256.

[369] M. Fahling, E. Seeliger, A. Patzak, et al., “Understanding and Preventing Contrast-Induced Acute Kidney Injury,” Nature Reviews Nephrology 13 (2017): 169–180.

[370] E. J. See, K. Jayasinghe, N. Glassford, et al., “Long-Term Risk of Adverse Outcomes After Acute Kidney Injury: A Systematic Review and Meta-Analysis of Cohort Studies Using Consensus Definitions of Exposure,” Kidney International 95 (2019): 160–172.

[371] P. Drawz and M. Rahman, “Chronic Kidney Disease,” Annals of Internal Medicine 162 (2015): ITC1–16.

[372] B. C. Lupsa and K. Insogna, “Bone Health and Osteoporosis,” Endocrinology and Metabolism Clinics of North America 44 (2015): 517–530.

[373] N. E. Lane, “Epidemiology, Etiology, and Diagnosis of Osteoporosis,” American Journal of Obstetrics and Gynecology 194 (2006): S3–S11.

[374] F. U. Bhatti, A. Karydis, B. S. Lee, et al., “Understanding Early-Stage Posttraumatic Osteoarthritis for Future Prospects of Diagnosis: From Knee to Temporomandibular Joint,” Current Osteoporosis Reports 19 (2021): 166–174.

[375] L. A. Mandl, “Osteoarthritis Year in Review 2018: Clinical,” Osteoarthritis and Cartilage 27 (2019): 359–364.

[376] G. Batshon, J. Elayyan, O. Qiq, et al., “Serum Nt/Ct Sirt1 Ratio Reflects Early Osteoarthritis and Chondrosenescence,” Annals of the Rheumatic Diseases 79 (2020): 1370–1380.

[377] Y. Jin, M. Liu, R. Sa, et al., “Mouse Models of Thyroid Cancer: Bridging Pathogenesis and Novel Therapeutics,” Cancer Letters 469 (2020): 35–53.

[378] E. A Mohamed, T. Gaber, O. Karam, and E. A. Rashed, “A Novel Cnn Pooling Layer for Breast Cancer Segmentation and Classification From Thermograms,” PLoS ONE 17 (2022): e0276523.

[379] L. E. L. Hendriks, J. Remon, C. Faivre-Finn, et al., “Non-Small-Cell Lung Cancer,” Nature reviews Disease primers 10 (2024): 71.

[380] E. S. Grebenshchikov, A. E. Pravednikova, E. E. Bezsonov, et al., “Linking Sirt1 Variants to Metabolic and Cardiovascular Phenotypes: Insights From Population Genetics and in Silico Structural Analysis,” Cell Biochemistry and Biophysics 84 (2026): 199–210.

[381] E. Sheikholmolouki, F. Sharifi, Z. Nickhah, et al., “The Association of the Sirt6 Rs117385980 Variant With Frailty and Longevity: An Exploratory Study,” Scientific Reports 15 (2025): 40251.

[382] K. Moonlisarn, P. Somnark, B. Boonkaew, et al., “Interaction Between Pnpla3 and Sirt5 Genetic Variants in Association With Liver Fibrosis Severity in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease,” Genes (Basel) 15 (2024): 1370.

[383] M. Springer and S. Moco, “Resveratrol and Its Human Metabolites-Effects on Metabolic Health and Obesity,” Nutrients 11 (2019): 143.

[384] J. C. Milne, P. D. Lambert, S. Schenk, et al., “Small Molecule Activators of Sirt1 as Therapeutics for the Treatment of Type 2 Diabetes,” Nature 450 (2007): 712–716.

[385] S. Venkatasubramanian, R. M. Noh, S. Daga, et al., “Effects of the Small Molecule Sirt1 Activator, Srt2104 on Arterial Stiffness in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus,” Open Heart 3 (2016): e000402.

[386] F. Spallotta, C. Cencioni, S. Straino, et al., “A Nitric Oxide-Dependent Cross-Talk Between Class I and Iii Histone Deacetylases Accelerates Skin Repair,” Journal of Biological Chemistry 288 (2013): 11004–11012.

[387] A. Carrizzo, C. Iside, A. Nebbioso, et al., “Sirt1 Pharmacological Activation Rescues Vascular Dysfunction and Prevents Thrombosis in Mthfr Deficiency,” Cellular and Molecular Life Sciences 79 (2022): 410.

[388] F. Xiang, Z. Zhang, Y. Li, et al., “Honokiol Targeting Sirt3: From Molecular Mechanisms to Therapeutic Opportunities,” Faseb Journal 39 (2025): e70798.

[389] J. Zhang, L. Zou, D. Shi, et al., “Structure-Guided Design of a Small-Molecule Activator of Sirtuin-3 That Modulates Autophagy in Triple Negative Breast Cancer,” Journal of Medicinal Chemistry 64 (2021): 14192–14216.

[390] Y. E. Cho, Y. Kim, H. Jo, et al., “Sirtuin 6 Activator Ubcs039 Ameliorates Hepatic Lipogenesis Through Liver X Receptor Deacetylation,” International Immunopharmacology 168 (2026): 115878.

[391] T. Ben Lulu, D. B. Manikandan, Y. Pevzner, et al., “Pharmacological Activation of Sirt6 Suppresses Progression of Head and Neck and Esophageal Squamous Cell Carcinoma by Modulation of Cellular Metabolism and Protein Translation,” Cell Death & Disease 16 (2025): 727.

[392] S. Wu, J. Zhang, C. Peng, et al., “Sirt6 Mediated Histone H3k9ac Deacetylation Involves Myocardial Remodelling Through Regulating Myocardial Energy Metabolism in Tac Mice,” Journal of Cellular and Molecular Medicine 27 (2023): 3451–3464.

[393] J. A. Collins, C. J. Kim, A. Coleman, et al., “Cartilage-Specific Sirt6 Deficiency Represses Igf-1 and Enhances Osteoarthritis Severity in Mice,” Annals of the Rheumatic Diseases 82 (2023): 1464–1473.

[394] T. Qin, W. Liu, J. Huo, et al., “Sirt1 Expression Regulates the Transformation of Resistant Esophageal Cancer Cells via the Epithelial-Mesenchymal Transition,” Biomedicine & Pharmacotherapy 103 (2018): 308–316.

[395] G. Chen, B. Zhang, H. Xu, et al., “Suppression of Sirt1 Sensitizes Lung Cancer Cells to Wee1 Inhibitor Mk-1775-Induced DNA Damage and Apoptosis,” Oncogene 36 (2017): 6863–6872.

[396] S. D. Sussmuth, S. Haider, G. B. Landwehrmeyer, et al., “An Exploratory Double-Blind, Randomized Clinical Trial With Selisistat, a Sirt1 Inhibitor, in Patients With Huntington's Disease,” British Journal of Clinical Pharmacology 79 (2015): 465–476.

[397] Q. Gao, L. Yang, S. Ye, et al., “Targeting Sirt2 Induces Mlh1 Deficiency and Boosts Antitumor Immunity in Preclinical Colorectal Cancer Models,” Science Translational Medicine 17 (2025): eadv0766.

[398] D. Hou, T. Yu, X. Lu, et al., “Sirt2 Inhibition Improves Gut Epithelial Barrier Integrity and Protects Mice From Colitis,” PNAS 121 (2024): e2319833121.

[399] Y. Luo, H. Zhao, J. Zhu, et al., “Sirt2 Inhibitor Sirreal2 Enhances Anti-Tumor Effects of Pi3k/Mtor Inhibitor vs-5584 on Acute Myeloid Leukemia Cells,” Cancer medicine 12 (2023): 18901–18917.

[400] A. S. Farooqi, J. Y. Hong, J. Cao, et al., “Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (Sirt2) With Anticancer Activity in a Colorectal Cancer Murine Model,” Journal of Medicinal Chemistry 62 (2019): 4131–4141.

[401] H. Jing, J. Hu, B. He, et al., “A Sirt2-Selective Inhibitor Promotes C-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity,” Cancer Cell 29 (2016): 297–310.

[402] F. Molinari, A. Feraco, S. Mirabilii, et al., “Sirt5 Inhibition Induces Brown Fat-Like Phenotype in 3t3-L1 Preadipocytes,” Cells 10 (2021): 1126.

[403] D. Yan, A. Franzini, A. D. Pomicter, et al., “Sirt5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia,” Blood Cancer Discovery 2 (2021): 266–287.

[404] J. Huang, J. Su, H. Wang, et al., “Discovery of Novel Protac Sirt6 Degraders With Potent Efficacy Against Hepatocellular Carcinoma,” Journal of Medicinal Chemistry 67 (2024): 17319–17349.

[405] J. Quan, X. Wen, G. Su, et al., “Epithelial Sirt6 Governs Il-17a Pathogenicity and Drives Allergic Airway Inflammation and Remodeling,” Nature Communications 14 (2023): 8525.

[406] N. Song, X. Guan, S. Zhang, et al., “Discovery of a Pyrrole-Pyridinimidazole Derivative as Novel Sirt6 Inhibitor for Sensitizing Pancreatic Cancer to Gemcitabine,” Cell Death & Disease 14 (2023): 499.

[407] J. H. Kim, D. Kim, S. J. Cho, et al., “Identification of a Novel Sirt7 Inhibitor as Anticancer Drug Candidate,” Biochemical and Biophysical Research Communications 508 (2019): 451–457.

[408] A. Kalhori, M. Rafraf, R. Navekar, et al., “Effect of Turmeric Supplementation on Blood Pressure and Serum Levels of Sirtuin 1 and Adiponectin in Patients With Nonalcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial,” Preventive Nutrition and Food Science 27 (2022): 37–44.

[409] M. Ghadimi, F. Foroughi, S. Hashemipour, et al., “Decreased Insulin Resistance in Diabetic Patients by Influencing Sirtuin1 and Fetuin-a Following Supplementation With Ellagic Acid: A Randomized Controlled Trial,” Diabetology & Metabolic Syndrome 13 (2021): 16.

[410] P. Safarpour, M. Daneshi-Maskooni, M. Vafa, et al., “Vitamin D Supplementation Improves Sirt1, Irisin, and Glucose Indices in Overweight or Obese Type 2 Diabetic Patients: A Double-Blind Randomized Placebo-Controlled Clinical Trial,” BMC Family Practice [Electronic Resource] 21 (2020): 26.

[411] M. Aghasi, F. Koohdani, M. Qorbani, et al., “Beneficial Effects of Green Cardamom on Serum Sirt1, Glycemic Indices and Triglyceride Levels in Patients With Type 2 Diabetes Mellitus: A Randomized Double-Blind Placebo Controlled Clinical Trial,” Journal of the Science of Food and Agriculture 99 (2019): 3933–3940.

[412] M. Daneshi-Maskooni, S. A. Keshavarz, M. Qorbani, et al., “Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial,” Nutrition & Metabolism (London) 15 (2018): 63.

[413] G. Sohrab, J. Nasrollahzadeh, M. Tohidi, et al., “Pomegranate Juice Increases Sirtuin1 Protein in Peripheral Blood Mononuclear Cell From Patients With Type 2 Diabetes: A Randomized Placebo Controlled Clinical Trial,” Metabolic Syndrome and Related Disorders 16 (2018): 446–451.

[414] D. Fiore, D. Gianfrilli, E. Giannetta, et al., “Pde5 Inhibition Ameliorates Visceral Adiposity Targeting the Mir-22/Sirt1 Pathway: Evidence From the Cecsid Trial,” Journal of Clinical Endocrinology and Metabolism 101 (2016): 1525–1534.

[415] S. Asghari, M. Asghari-Jafarabadi, M. H. Somi, et al., “Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial,” Journal of the American College of Nutrition 37 (2018): 223–233.

[416] S. Bo, G. Togliatto, R. Gambino, et al., “Impact of Sirtuin-1 Expression on H3k56 Acetylation and Oxidative Stress: A Double-Blind Randomized Controlled Trial With Resveratrol Supplementation,” Acta Diabetologica 55 (2018): 331–340.

[417] S. V. De Kreutzenberg, G. Ceolotto, A. Cattelan, et al., “Metformin Improves Putative Longevity Effectors in Peripheral Mononuclear Cells From Subjects With Prediabetes. A Randomized Controlled Trial,” Nutrition, Metabolism and Cardiovascular Diseases 25 (2015): 686–693.

[418] P. Wasserfurth, J. Nebl, M. R. Ruhling, et al., “Impact of Dietary Modifications on Plasma Sirtuins 1, 3 and 5 in Older Overweight Individuals Undergoing 12-Weeks of Circuit Training,” Nutrients 13 (2021): 3824.

[419] S. Saboori, F. Koohdani, E. Nematipour, et al., “Beneficial Effects of Omega-3 and Vitamin E Coadministration on Gene Expression of Sirt1 and Pgc1alpha and Serum Antioxidant Enzymes in Patients With Coronary Artery Disease,” Nutrition, Metabolism and Cardiovascular Diseases 26 (2016): 489–494.

[420] N. Abedimanesh, B. Motlagh, S. Abedimanesh, et al., “Effects of Crocin and Saffron Aqueous Extract on Gene Expression of Sirt1, Ampk, Lox1, Nf-Kappab, and Mcp-1 in Patients With Coronary Artery Disease: A Randomized Placebo-Controlled Clinical Trial,” Phytotherapy Research 34 (2020): 1114–1122.

[421] S. Abedimanesh, S. Z. Bathaie, A. Ostadrahimi, et al., “The Effect of Crocetin Supplementation on Markers of Atherogenic Risk in Patients With Coronary Artery Disease: A Pilot, Randomized, Double-Blind, Placebo-Controlled Clinical Trial,” Food Function 10 (2019): 7461–7475.

[422] S. Gautam, U. Kumar, M. Kumar, et al., “Yoga Improves Mitochondrial Health and Reduces Severity of Autoimmune Inflammatory Arthritis: A Randomized Controlled Trial,” Mitochondrion 58 (2021): 147–159.

[423] M. Khazdouz, N. E. Daryani, F. Alborzi, et al., “Effect of Selenium Supplementation on Expression of Sirt1 and Pgc-1alpha Genes in Ulcerative Colitis Patients: A Double Blind Randomized Clinical Trial,” Clinical Nutrition Research 9 (2020): 284–295.

[424] S. Gautam, M. Kumar, U. Kumar, et al., “Effect of an 8-Week Yoga-Based Lifestyle Intervention on Psycho-Neuro-Immune Axis, Disease Activity, and Perceived Quality of Life in Rheumatoid Arthritis Patients: A Randomized Controlled Trial,” Frontiers in Psychology 11 (2020): 2259.

[425] B. E. Sands, S. Joshi, J. Haddad, et al., “Assessing Colonic Exposure, Safety, and Clinical Activity of Srt2104, a Novel Oral Sirt1 Activator, in Patients With Mild to Moderate Ulcerative Colitis,” Inflammatory Bowel Diseases 22 (2016): 607–614.

[426] J. E. Amengual, S. Clark-Garvey, M. Kalac, et al., “Sirtuin and Pan-Class I/Ii Deacetylase (Dac) Inhibition Is Synergistic in Preclinical Models and Clinical Studies of Lymphoma,” Blood 122 (2013): 2104–2113.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.